organization · Reporting owner

Foresite Capital Management V, LLC

Disclosed activity across 8 companies

Tapewire entity: 25098
SEC CIK: 0001792206

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
ALUMIS INC.ALMS · Entity 4816	10% owner	April 01, 2026	April 03, 2026
Disc Medicine, Inc.GMTX · Entity 2273	10% owner · Director by Deputization	February 05, 2021	February 09, 2021
Latigo Biotherapeutics, Inc.LTGO · Entity 4709	10% owner	August 10, 2026	August 11, 2026
PARDES BIOSCIENCES, INC.PRDS · Entity 110063	10% owner	August 31, 2023	August 31, 2023
Theseus Pharmaceuticals, Inc.THRX · Entity 94301	10% owner	July 17, 2023	July 19, 2023

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

ALUMIS INC.

Report date April 01, 2026 · Filed April 03, 2026

Jointly reported with Foresite Capital Management VI LLC, Foresite Capital Fund V, L.P., Foresite Capital Opportunity Management V, LLC, Foresite Capital Opportunity Fund V, L.P., Foresite Capital Fund VI LP, Labs Co-Invest V, LLC, Foresite Labs Management I, LLC, Foresite Labs Fund I, L.P.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee Footnote	0	Reported balance After 2026-04-01 transaction · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · 2026-04-01 · Other · Disposed 1,176,470 · Balance 0 F1: Represents a pro rata, in-kind distribution, and not a purchase or sale, without additional consideration by Foresite Labs Affiliates 2021, LLC ("Labs Affiliates") to its members in accordance with the exemptions afforded by Rules 16a-13 and/or 16a-9 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). F2: The shares are held of record by Labs Affiliates. Foresite Labs, LLC ("Labs") is the managing member of Labs Affiliates and may be deemed to have sole voting and dispositive power over such shares. James B. Tananbaum ("Tananbaum"), a manager of Labs, may be deemed to share voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Exchange Act, and disclaims beneficial ownership of the shares held by Labs Affiliates, except to the extent of such person's pecuniary interest in such securities.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	1,123,337	Reported balance After 2026-04-01 transaction · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · 2026-04-01 · Other · Acquired 1,123,337 · Balance 1,123,337 F3: Represents shares received by Labs pursuant to pro rata distributions by Labs Affiliates, for no consideration, to its members in accordance with the exemptions afforded by Rules 16a-13 and/or 16a-9 of the Exchange Act. F4: The shares are held of record by Labs. Tananbaum, a manager of Labs, may be deemed to share voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Exchange Act, and disclaims beneficial ownership of the shares held by Labs, except to the extent of such person's pecuniary interest in such securities.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	0	Reported balance After 2026-04-01 transaction · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · 2026-04-01 · Other · Disposed 1,123,337 · Balance 0 F5: Represents a pro rata, in-kind distribution, and not a purchase or sale, without additional consideration by Labs to its members in accordance with the exemptions afforded by Rules 16a-13 and/or 16a-9 of the Exchange Act. F4: The shares are held of record by Labs. Tananbaum, a manager of Labs, may be deemed to share voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Exchange Act, and disclaims beneficial ownership of the shares held by Labs, except to the extent of such person's pecuniary interest in such securities.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	680,486	Reported balance After 2026-04-01 transaction · row 4 Holding and transaction disclosures are not merged. 1 source row Row 4 · 2026-04-01 · Other · Acquired 680,486 · Balance 680,486 F6: Represents shares received by TFL Investment Holdings, LLC ("TFL"). pursuant to pro rata distributions by Labs, for no consideration, to its members in accordance with the exemptions afforded by Rules 16a-13 and/or 16a-9 of the Exchange Act. F7: The shares are held of record by TFL. Tananbaum is the manager of TFL, and James B. Tananbaum and Dana Shonfeld Tananbaum Family Trust, of which Tananbaum is a trustee, is the sole member of TFL. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Exchange Act, and disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that any such person is the beneficial owner of such securities, except to the extent of such person's pecuniary interest therein, if any.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	5,702,536	Reported balance Holding disclosure · report date 2026-04-01 · row 5 Holding and transaction disclosures are not merged. 1 source row Row 5 · Balance 5,702,536 F8: The shares are held of record by Foresite Capital Fund V, L.P. ("Fund V"). Foresite Capital Management V, LLC ("FCM V") is the general partner of Fund V and may be deemed to have sole voting and dispositive power over such shares. Tananbaum, the managing member of FCM V, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Exchange Act, and, other than Fund V, disclaims beneficial ownership of the shares held by Fund V, except to the extent of such person's pecuniary interest in such securities.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	2,908,332	Reported balance Holding disclosure · report date 2026-04-01 · row 6 Holding and transaction disclosures are not merged. 1 source row Row 6 · Balance 2,908,332 F9: The shares are held of record by Foresite Capital Opportunity Fund V, L.P. ("Opportunity Fund V"). Foresite Capital Opportunity Management V, LLC ("FCOM V") is the general partner of Opportunity Fund V and may be deemed to have sole voting and dispositive power over such shares. Tananbaum, the managing member of FCOM V, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Exchange Act, and, other than Opportunity Fund V, disclaims beneficial ownership of the shares held by Opportunity Fund V, except to the extent of such person's pecuniary interest in such securities.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	4,247,670	Reported balance Holding disclosure · report date 2026-04-01 · row 7 Holding and transaction disclosures are not merged. 1 source row Row 7 · Balance 4,247,670 F10: The shares are held of record by Foresite Capital Fund VI, L.P. ("Fund VI"). Foresite Capital Management VI, LLC ("FCM VI") is the general partner of Fund VI and may be deemed to have sole voting and dispositive power over such shares. Tananbaum, the managing member of FCM VI, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Exchange Act, and, other than Fund VI, disclaims beneficial ownership of the shares held by Fund VI, except to the extent of such person's pecuniary interest in such securities.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	194,459	Reported balance Holding disclosure · report date 2026-04-01 · row 8 Holding and transaction disclosures are not merged. 1 source row Row 8 · Balance 194,459 F11: The shares are held of record by Labs Co-Invest V, LLC ("Labs Co-Invest"). FCM V is the managing member of Labs Co-Invest and may be deemed to have sole voting and dispositive power over such shares. Tananbaum, the managing member of FCM V, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Exchange Act, and, other than Labs Co-Invest, disclaims beneficial ownership of the shares held by Labs Co-Invest, except to the extent of such person's pecuniary interest in such securities.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	1,960,337	Reported balance Holding disclosure · report date 2026-04-01 · row 9 Holding and transaction disclosures are not merged. 1 source row Row 9 · Balance 1,960,337 F12: The shares are held of record by Foresite Labs Fund I, L.P. ("Labs Fund I"). Foresite Labs Management I, LLC ("FLM I") is the general partner of Labs Fund I and may be deemed to have sole voting and dispositive power over such shares. Tananbaum, the managing member of FLM I, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Exchange Act, and, other than Labs Fund I, disclaims beneficial ownership of the shares held by Labs Fund I, except to the extent of such person's pecuniary interest in such securities.

Filing footnotes · ownership attribution and instrument terms

F1: Represents a pro rata, in-kind distribution, and not a purchase or sale, without additional consideration by Foresite Labs Affiliates 2021, LLC ("Labs Affiliates") to its members in accordance with the exemptions afforded by Rules 16a-13 and/or 16a-9 of the Securities Exchange Act of 1934, as amended (the "Exchange Act").

F2: The shares are held of record by Labs Affiliates. Foresite Labs, LLC ("Labs") is the managing member of Labs Affiliates and may be deemed to have sole voting and dispositive power over such shares. James B. Tananbaum ("Tananbaum"), a manager of Labs, may be deemed to share voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Exchange Act, and disclaims beneficial ownership of the shares held by Labs Affiliates, except to the extent of such person's pecuniary interest in such securities.

F3: Represents shares received by Labs pursuant to pro rata distributions by Labs Affiliates, for no consideration, to its members in accordance with the exemptions afforded by Rules 16a-13 and/or 16a-9 of the Exchange Act.

F4: The shares are held of record by Labs. Tananbaum, a manager of Labs, may be deemed to share voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Exchange Act, and disclaims beneficial ownership of the shares held by Labs, except to the extent of such person's pecuniary interest in such securities.

F5: Represents a pro rata, in-kind distribution, and not a purchase or sale, without additional consideration by Labs to its members in accordance with the exemptions afforded by Rules 16a-13 and/or 16a-9 of the Exchange Act.

F6: Represents shares received by TFL Investment Holdings, LLC ("TFL"). pursuant to pro rata distributions by Labs, for no consideration, to its members in accordance with the exemptions afforded by Rules 16a-13 and/or 16a-9 of the Exchange Act.

F7: The shares are held of record by TFL. Tananbaum is the manager of TFL, and James B. Tananbaum and Dana Shonfeld Tananbaum Family Trust, of which Tananbaum is a trustee, is the sole member of TFL. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Exchange Act, and disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that any such person is the beneficial owner of such securities, except to the extent of such person's pecuniary interest therein, if any.

F8: The shares are held of record by Foresite Capital Fund V, L.P. ("Fund V"). Foresite Capital Management V, LLC ("FCM V") is the general partner of Fund V and may be deemed to have sole voting and dispositive power over such shares. Tananbaum, the managing member of FCM V, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Exchange Act, and, other than Fund V, disclaims beneficial ownership of the shares held by Fund V, except to the extent of such person's pecuniary interest in such securities.

F9: The shares are held of record by Foresite Capital Opportunity Fund V, L.P. ("Opportunity Fund V"). Foresite Capital Opportunity Management V, LLC ("FCOM V") is the general partner of Opportunity Fund V and may be deemed to have sole voting and dispositive power over such shares. Tananbaum, the managing member of FCOM V, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Exchange Act, and, other than Opportunity Fund V, disclaims beneficial ownership of the shares held by Opportunity Fund V, except to the extent of such person's pecuniary interest in such securities.

F10: The shares are held of record by Foresite Capital Fund VI, L.P. ("Fund VI"). Foresite Capital Management VI, LLC ("FCM VI") is the general partner of Fund VI and may be deemed to have sole voting and dispositive power over such shares. Tananbaum, the managing member of FCM VI, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Exchange Act, and, other than Fund VI, disclaims beneficial ownership of the shares held by Fund VI, except to the extent of such person's pecuniary interest in such securities.

F11: The shares are held of record by Labs Co-Invest V, LLC ("Labs Co-Invest"). FCM V is the managing member of Labs Co-Invest and may be deemed to have sole voting and dispositive power over such shares. Tananbaum, the managing member of FCM V, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Exchange Act, and, other than Labs Co-Invest, disclaims beneficial ownership of the shares held by Labs Co-Invest, except to the extent of such person's pecuniary interest in such securities.

F12: The shares are held of record by Foresite Labs Fund I, L.P. ("Labs Fund I"). Foresite Labs Management I, LLC ("FLM I") is the general partner of Labs Fund I and may be deemed to have sole voting and dispositive power over such shares. Tananbaum, the managing member of FLM I, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Exchange Act, and, other than Labs Fund I, disclaims beneficial ownership of the shares held by Labs Fund I, except to the extent of such person's pecuniary interest in such securities.

Disc Medicine, Inc.

Report date February 05, 2021 · Filed February 09, 2021

Jointly reported with FS Development Holdings, LLC, Foresite Capital Fund V, L.P., Foresite Capital Opportunity Fund V, L.P., Foresite Capital Opportunity Management V, LLC

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	1,500,000	Reported balance After 2021-02-05 transaction · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · 2021-02-05 · Grant · Acquired 1,500,000 · Balance 1,500,000 F1: Shares of common stock obtained in private placement of public securities ("PIPE") on February 5, 2021. F2: These shares of the Issuer's common stock are held of record by FS Development Holdings, LLC ("FSD Holdings"). Foresite Capital Management V LLC ("FCMVLLC") and Foresite Capital Opportunity Management V, LLC ("FCOMVLLC") are general partners, respectively, of Foresite Capital Fund V, L.P. ("Capital Fund V L.P.") and Foresite Capital Opportunity Fund V, L.P. ("Opportunity Fund V .L.P."), the sole shareholders of FSD Holdings. Each of FCMVLLC, FCOMVLLC, Capital Fund V L.P and Opportunity Fund V L.P. disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein.
Common StockSEC Table I · non-derivative	Direct	2,928,750	Reported balance After 2021-02-05 transaction · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · 2021-02-05 · Conversion · Acquired 2,928,750 · Balance 2,928,750 F3: In connection with the closing of Gemini Therapeutics, Inc.'s (formerly known as FS Development Corp.) business combination, shares of Class B Common Stock of FS Development Corp. converted into common stock of the Issuer . F2: These shares of the Issuer's common stock are held of record by FS Development Holdings, LLC ("FSD Holdings"). Foresite Capital Management V LLC ("FCMVLLC") and Foresite Capital Opportunity Management V, LLC ("FCOMVLLC") are general partners, respectively, of Foresite Capital Fund V, L.P. ("Capital Fund V L.P.") and Foresite Capital Opportunity Fund V, L.P. ("Opportunity Fund V .L.P."), the sole shareholders of FSD Holdings. Each of FCMVLLC, FCOMVLLC, Capital Fund V L.P and Opportunity Fund V L.P. disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein.
Common StockSEC Table I · non-derivative	Direct	441,500	Reported balance Holding disclosure · report date 2021-02-05 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 441,500 F2: These shares of the Issuer's common stock are held of record by FS Development Holdings, LLC ("FSD Holdings"). Foresite Capital Management V LLC ("FCMVLLC") and Foresite Capital Opportunity Management V, LLC ("FCOMVLLC") are general partners, respectively, of Foresite Capital Fund V, L.P. ("Capital Fund V L.P.") and Foresite Capital Opportunity Fund V, L.P. ("Opportunity Fund V .L.P."), the sole shareholders of FSD Holdings. Each of FCMVLLC, FCOMVLLC, Capital Fund V L.P and Opportunity Fund V L.P. disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein.
Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	0	Reported balance After 2021-02-05 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2021-02-05 · Conversion · Disposed 2,928,750 · Balance 0 F3: In connection with the closing of Gemini Therapeutics, Inc.'s (formerly known as FS Development Corp.) business combination, shares of Class B Common Stock of FS Development Corp. converted into common stock of the Issuer . F2: These shares of the Issuer's common stock are held of record by FS Development Holdings, LLC ("FSD Holdings"). Foresite Capital Management V LLC ("FCMVLLC") and Foresite Capital Opportunity Management V, LLC ("FCOMVLLC") are general partners, respectively, of Foresite Capital Fund V, L.P. ("Capital Fund V L.P.") and Foresite Capital Opportunity Fund V, L.P. ("Opportunity Fund V .L.P."), the sole shareholders of FSD Holdings. Each of FCMVLLC, FCOMVLLC, Capital Fund V L.P and Opportunity Fund V L.P. disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: Shares of common stock obtained in private placement of public securities ("PIPE") on February 5, 2021.

F2: These shares of the Issuer's common stock are held of record by FS Development Holdings, LLC ("FSD Holdings"). Foresite Capital Management V LLC ("FCMVLLC") and Foresite Capital Opportunity Management V, LLC ("FCOMVLLC") are general partners, respectively, of Foresite Capital Fund V, L.P. ("Capital Fund V L.P.") and Foresite Capital Opportunity Fund V, L.P. ("Opportunity Fund V .L.P."), the sole shareholders of FSD Holdings. Each of FCMVLLC, FCOMVLLC, Capital Fund V L.P and Opportunity Fund V L.P. disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein.

F3: In connection with the closing of Gemini Therapeutics, Inc.'s (formerly known as FS Development Corp.) business combination, shares of Class B Common Stock of FS Development Corp. converted into common stock of the Issuer .

Latigo Biotherapeutics, Inc.

Report date August 10, 2026 · Filed August 11, 2026

Jointly reported with Foresite Capital Fund V, L.P., Foresite Capital Opportunity Management V, LLC, Foresite Capital Opportunity Fund V, L.P., Foresite Capital Management VI LLC, Foresite Capital Fund VI LP

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee Footnote	3,117,664	Reported balance After 2026-08-10 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2026-08-10 · Conversion · Acquired 3,117,664 · Balance 3,117,664 F1: Each share of the Issuer's preferred stock converted automatically into 1 share of common stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The preferred stock had no expiration date. F2: The securities are held of record by Foresite Capital Fund V, L.P. ("Fund V"). Foresite Capital Management V, LLC ("FCM V") is the general partner of Fund V and may be deemed to have sole voting and dispositive power over the securities held by Fund V. James B. Tananbaum (Tananbaum) is the sole managing member of FCM V and may be deemed to have sole voting and dispositive power over the securities held by Fund V. Each of the Reporting Persons disclaims the existence of a "group" and disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	3,562,984	Reported balance After 2026-08-10 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2026-08-10 · Conversion · Acquired 445,320 · Balance 3,562,984 F1: Each share of the Issuer's preferred stock converted automatically into 1 share of common stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The preferred stock had no expiration date. F2: The securities are held of record by Foresite Capital Fund V, L.P. ("Fund V"). Foresite Capital Management V, LLC ("FCM V") is the general partner of Fund V and may be deemed to have sole voting and dispositive power over the securities held by Fund V. James B. Tananbaum (Tananbaum) is the sole managing member of FCM V and may be deemed to have sole voting and dispositive power over the securities held by Fund V. Each of the Reporting Persons disclaims the existence of a "group" and disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	1,125,823	Reported balance After 2026-08-10 transaction · row 3 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 3 · 2026-08-10 · Conversion · Acquired 1,125,823 · Balance 1,125,823 F1: Each share of the Issuer's preferred stock converted automatically into 1 share of common stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The preferred stock had no expiration date. F3: The securities are held of record by Foresite Capital Fund VI LP ("Fund VI"). Foresite Capital Management VI, LLC ("FCM VI") is the general partner of Fund VI and may be deemed to have sole voting and dispositive power over the securities held by Fund VI. Tananbaum is the sole managing member of FCM VI and may be deemed to have sole voting and dispositive power over the securities held by Fund VI. Each of the Reporting Persons disclaims the existence of a "group" and disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	1,868,024	Reported balance After 2026-08-10 transaction · row 4 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 4 · 2026-08-10 · Conversion · Acquired 742,201 · Balance 1,868,024 F1: Each share of the Issuer's preferred stock converted automatically into 1 share of common stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The preferred stock had no expiration date. F3: The securities are held of record by Foresite Capital Fund VI LP ("Fund VI"). Foresite Capital Management VI, LLC ("FCM VI") is the general partner of Fund VI and may be deemed to have sole voting and dispositive power over the securities held by Fund VI. Tananbaum is the sole managing member of FCM VI and may be deemed to have sole voting and dispositive power over the securities held by Fund VI. Each of the Reporting Persons disclaims the existence of a "group" and disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	2,008,024	Reported balance After 2026-08-10 transaction · row 5 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 5 · 2026-08-10 · Purchase · Acquired 140,000 · Balance 2,008,024 F3: The securities are held of record by Foresite Capital Fund VI LP ("Fund VI"). Foresite Capital Management VI, LLC ("FCM VI") is the general partner of Fund VI and may be deemed to have sole voting and dispositive power over the securities held by Fund VI. Tananbaum is the sole managing member of FCM VI and may be deemed to have sole voting and dispositive power over the securities held by Fund VI. Each of the Reporting Persons disclaims the existence of a "group" and disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	2,203,800	Reported balance After 2026-08-10 transaction · row 6 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 6 · 2026-08-10 · Conversion · Acquired 195,776 · Balance 2,203,800 F1: Each share of the Issuer's preferred stock converted automatically into 1 share of common stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The preferred stock had no expiration date. F5: Reflects a convertible note that is convertible into shares of Common Stock of the Issuer. The convertible note has a maturity date of June 17, 2027. The principal amount of the convertible note together with any accrued but unpaid interest automatically converted into shares of Common Stock of the Issuer upon the closing of the Issuer's initial public offering at a conversion price equal to the initial public offering price of the Issuer's common stock. F3: The securities are held of record by Foresite Capital Fund VI LP ("Fund VI"). Foresite Capital Management VI, LLC ("FCM VI") is the general partner of Fund VI and may be deemed to have sole voting and dispositive power over the securities held by Fund VI. Tananbaum is the sole managing member of FCM VI and may be deemed to have sole voting and dispositive power over the securities held by Fund VI. Each of the Reporting Persons disclaims the existence of a "group" and disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	3,117,664	Reported balance After 2026-08-10 transaction · row 7 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 7 · 2026-08-10 · Conversion · Acquired 3,117,664 · Balance 3,117,664 F1: Each share of the Issuer's preferred stock converted automatically into 1 share of common stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The preferred stock had no expiration date. F4: The securities are held of record by Foresite Capital Opportunity Fund V, L.P. ("Opportunity Fund V"). Foresite Capital Opportunity Management V, LLC ("FCOM V") is the general partner of Opportunity Fund V and may be deemed to have sole voting and dispositive power over the shares held by Opportunity Fund V. Tananbaum is the sole managing member of FCOM V and may be deemed to have sole voting and dispositive power over the securities held by Opportunity Fund V. Each of the Reporting Persons disclaims the existence of a "group" and disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	3,414,544	Reported balance After 2026-08-10 transaction · row 8 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 8 · 2026-08-10 · Conversion · Acquired 296,880 · Balance 3,414,544 F1: Each share of the Issuer's preferred stock converted automatically into 1 share of common stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The preferred stock had no expiration date. F4: The securities are held of record by Foresite Capital Opportunity Fund V, L.P. ("Opportunity Fund V"). Foresite Capital Opportunity Management V, LLC ("FCOM V") is the general partner of Opportunity Fund V and may be deemed to have sole voting and dispositive power over the shares held by Opportunity Fund V. Tananbaum is the sole managing member of FCOM V and may be deemed to have sole voting and dispositive power over the securities held by Opportunity Fund V. Each of the Reporting Persons disclaims the existence of a "group" and disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.
Series A-2 Convertible Preferred StockSEC Table II · derivative / convertible security	IndirectSee Footnote	0	Reported balance After 2026-08-10 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2026-08-10 · Conversion · Disposed 3,117,664 · Balance 0 F1: Each share of the Issuer's preferred stock converted automatically into 1 share of common stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The preferred stock had no expiration date. F2: The securities are held of record by Foresite Capital Fund V, L.P. ("Fund V"). Foresite Capital Management V, LLC ("FCM V") is the general partner of Fund V and may be deemed to have sole voting and dispositive power over the securities held by Fund V. James B. Tananbaum (Tananbaum) is the sole managing member of FCM V and may be deemed to have sole voting and dispositive power over the securities held by Fund V. Each of the Reporting Persons disclaims the existence of a "group" and disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.
Series A-2 Convertible Preferred StockSEC Table II · derivative / convertible security	IndirectSee Footnote	0	Reported balance After 2026-08-10 transaction · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · 2026-08-10 · Conversion · Disposed 1,125,823 · Balance 0 F1: Each share of the Issuer's preferred stock converted automatically into 1 share of common stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The preferred stock had no expiration date. F3: The securities are held of record by Foresite Capital Fund VI LP ("Fund VI"). Foresite Capital Management VI, LLC ("FCM VI") is the general partner of Fund VI and may be deemed to have sole voting and dispositive power over the securities held by Fund VI. Tananbaum is the sole managing member of FCM VI and may be deemed to have sole voting and dispositive power over the securities held by Fund VI. Each of the Reporting Persons disclaims the existence of a "group" and disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.
Series A-2 Convertible Preferred StockSEC Table II · derivative / convertible security	IndirectSee Footnote	0	Reported balance After 2026-08-10 transaction · row 13 Instrument identity requires review; Table II rows are not merged. 1 source row Row 13 · 2026-08-10 · Conversion · Disposed 3,117,664 · Balance 0 F1: Each share of the Issuer's preferred stock converted automatically into 1 share of common stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The preferred stock had no expiration date. F4: The securities are held of record by Foresite Capital Opportunity Fund V, L.P. ("Opportunity Fund V"). Foresite Capital Opportunity Management V, LLC ("FCOM V") is the general partner of Opportunity Fund V and may be deemed to have sole voting and dispositive power over the shares held by Opportunity Fund V. Tananbaum is the sole managing member of FCOM V and may be deemed to have sole voting and dispositive power over the securities held by Opportunity Fund V. Each of the Reporting Persons disclaims the existence of a "group" and disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.
Series B Convertible Preferred StockSEC Table II · derivative / convertible security	IndirectSee Footnote	0	Reported balance After 2026-08-10 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2026-08-10 · Conversion · Disposed 445,320 · Balance 0 F1: Each share of the Issuer's preferred stock converted automatically into 1 share of common stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The preferred stock had no expiration date. F2: The securities are held of record by Foresite Capital Fund V, L.P. ("Fund V"). Foresite Capital Management V, LLC ("FCM V") is the general partner of Fund V and may be deemed to have sole voting and dispositive power over the securities held by Fund V. James B. Tananbaum (Tananbaum) is the sole managing member of FCM V and may be deemed to have sole voting and dispositive power over the securities held by Fund V. Each of the Reporting Persons disclaims the existence of a "group" and disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.
Series B Convertible Preferred StockSEC Table II · derivative / convertible security	IndirectSee Footnote	0	Reported balance After 2026-08-10 transaction · row 12 Instrument identity requires review; Table II rows are not merged. 1 source row Row 12 · 2026-08-10 · Conversion · Disposed 742,201 · Balance 0 F1: Each share of the Issuer's preferred stock converted automatically into 1 share of common stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The preferred stock had no expiration date. F3: The securities are held of record by Foresite Capital Fund VI LP ("Fund VI"). Foresite Capital Management VI, LLC ("FCM VI") is the general partner of Fund VI and may be deemed to have sole voting and dispositive power over the securities held by Fund VI. Tananbaum is the sole managing member of FCM VI and may be deemed to have sole voting and dispositive power over the securities held by Fund VI. Each of the Reporting Persons disclaims the existence of a "group" and disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.
Series B Convertible Preferred StockSEC Table II · derivative / convertible security	IndirectSee Footnote	0	Reported balance After 2026-08-10 transaction · row 14 Instrument identity requires review; Table II rows are not merged. 1 source row Row 14 · 2026-08-10 · Conversion · Disposed 296,880 · Balance 0 F1: Each share of the Issuer's preferred stock converted automatically into 1 share of common stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The preferred stock had no expiration date. F4: The securities are held of record by Foresite Capital Opportunity Fund V, L.P. ("Opportunity Fund V"). Foresite Capital Opportunity Management V, LLC ("FCOM V") is the general partner of Opportunity Fund V and may be deemed to have sole voting and dispositive power over the shares held by Opportunity Fund V. Tananbaum is the sole managing member of FCOM V and may be deemed to have sole voting and dispositive power over the securities held by Opportunity Fund V. Each of the Reporting Persons disclaims the existence of a "group" and disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.
Convertible Promissory NoteSEC Table II · derivative / convertible security	IndirectSee Footnote	0	Reported balance After 2026-08-10 transaction · row 15 Instrument identity requires review; Table II rows are not merged. 1 source row Row 15 · 2026-08-10 · Conversion · Disposed 195,776 · Balance 0 F5: Reflects a convertible note that is convertible into shares of Common Stock of the Issuer. The convertible note has a maturity date of June 17, 2027. The principal amount of the convertible note together with any accrued but unpaid interest automatically converted into shares of Common Stock of the Issuer upon the closing of the Issuer's initial public offering at a conversion price equal to the initial public offering price of the Issuer's common stock. F3: The securities are held of record by Foresite Capital Fund VI LP ("Fund VI"). Foresite Capital Management VI, LLC ("FCM VI") is the general partner of Fund VI and may be deemed to have sole voting and dispositive power over the securities held by Fund VI. Tananbaum is the sole managing member of FCM VI and may be deemed to have sole voting and dispositive power over the securities held by Fund VI. Each of the Reporting Persons disclaims the existence of a "group" and disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: Each share of the Issuer's preferred stock converted automatically into 1 share of common stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The preferred stock had no expiration date.

F2: The securities are held of record by Foresite Capital Fund V, L.P. ("Fund V"). Foresite Capital Management V, LLC ("FCM V") is the general partner of Fund V and may be deemed to have sole voting and dispositive power over the securities held by Fund V. James B. Tananbaum (Tananbaum) is the sole managing member of FCM V and may be deemed to have sole voting and dispositive power over the securities held by Fund V. Each of the Reporting Persons disclaims the existence of a "group" and disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.

F3: The securities are held of record by Foresite Capital Fund VI LP ("Fund VI"). Foresite Capital Management VI, LLC ("FCM VI") is the general partner of Fund VI and may be deemed to have sole voting and dispositive power over the securities held by Fund VI. Tananbaum is the sole managing member of FCM VI and may be deemed to have sole voting and dispositive power over the securities held by Fund VI. Each of the Reporting Persons disclaims the existence of a "group" and disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.

F4: The securities are held of record by Foresite Capital Opportunity Fund V, L.P. ("Opportunity Fund V"). Foresite Capital Opportunity Management V, LLC ("FCOM V") is the general partner of Opportunity Fund V and may be deemed to have sole voting and dispositive power over the shares held by Opportunity Fund V. Tananbaum is the sole managing member of FCOM V and may be deemed to have sole voting and dispositive power over the securities held by Opportunity Fund V. Each of the Reporting Persons disclaims the existence of a "group" and disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.

F5: Reflects a convertible note that is convertible into shares of Common Stock of the Issuer. The convertible note has a maturity date of June 17, 2027. The principal amount of the convertible note together with any accrued but unpaid interest automatically converted into shares of Common Stock of the Issuer upon the closing of the Issuer's initial public offering at a conversion price equal to the initial public offering price of the Issuer's common stock.

PARDES BIOSCIENCES, INC.

Report date August 31, 2023 · Filed August 31, 2023

Jointly reported with Tananbaum James B., FS Development Holdings II, LLC, Foresite Capital Opportunity Fund V, L.P., Foresite Capital Opportunity Management V, LLC, Foresite Capital Fund V, L.P.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee Footnote	0	Reported balance After 2023-08-31 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2023-08-31 · Disposition to issuer · Disposed 16,813,146 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated July 16, 2023, by and among Pardes Biosciences, Inc. (the "Issuer"), MediPacific, Inc. ("Parent") and MediPacific Sub, Inc. ("Purchaser"), a wholly-owned subsidiary of Parent, pursuant to which Purchaser completed a tender offer (the "Offer") for shares of the Issuer, $0.0001 par value per share, and thereafter merged with and into the Issuer (the "Merger") effective as of August 31, 2023 (the "Effective Time"). In accordance with the terms of the Merger Agreement, at the Effective Time, the 16,813,146 shares beneficially owned by the Reporting Persons were automatically cancelled for no consideration. F2: Consisted of shares beneficially owned by FS Development Holdings II, LLC, Foresite Capital Management V, LLC, Foresite Capital Opportunity Fund V, L.P., Foresite Capital Opportunity Management V, LLC and Foresite Capital Fund V, L.P., and of which Dr. Tananbaum may be deemed to have had a pecuniary interest.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	1,000	Reported balance After 2023-08-31 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2023-08-31 · Other · Acquired 1,000 · Balance 1,000 F3: At the Effective Time, Merger Sub merged with and into the Issuer pursuant to Section 251(h) of the Delaware General Corporation Law, and each share of common stock of Merger Sub issued and outstanding immediately before the Effective Time automatically converted into and became one share of common stock, par value $0.0001 of the Issuer (representing 1,000 shares in the aggregate), with the Issuer surviving as a wholly owned subsidiary of Parent. F4: The shares are beneficially owned by Parent. Parent is wholly owned by Foresite Capital Opportunity Fund V, L.P. Dr. Tananbaum is the managing member of Foresite Capital Opportunity Management V, LLC, which is the general partner of Foresite Capital Opportunity Fund V, L.P. Dr. Tananbaum may be deemed to have a pecuniary interest in the shares beneficially owned by Parent.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.87 · Expires 2033-05-31	Direct	0	Reported balance After 2023-08-31 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2023-08-31 · Disposition to issuer · Acquired 37,500 · Balance 0 F5: On July 16, 2023, the Issuer's Board of Directors vested in full each option to purchase shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested as of that date. As of the Effective Time, each in-the-money Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled in-the-money Company Stock Option was entitled to receive, in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings and without interest) equal to the product of (x) the total number of shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess of $2.13 over the applicable exercise price per share under such Company Stock Option and (ii) one contingent value right for each share subject thereto.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.21 · Expires 2032-06-07	Direct	0	Reported balance After 2023-08-31 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2023-08-31 · Disposition to issuer · Acquired 37,500 · Balance 0 F6: On July 16, 2023, the Issuer's Board of Directors vested in full each unvested Company Stock Option. Pursuant to the Merger Agreement, each Company Stock Option that was not in the money as of the Effective Time was cancelled for no consideration at the Effective Time.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.80 · Expires 2031-12-22	Direct	0	Reported balance After 2023-08-31 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2023-08-31 · Disposition to issuer · Acquired 75,000 · Balance 0 F6: On July 16, 2023, the Issuer's Board of Directors vested in full each unvested Company Stock Option. Pursuant to the Merger Agreement, each Company Stock Option that was not in the money as of the Effective Time was cancelled for no consideration at the Effective Time.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated July 16, 2023, by and among Pardes Biosciences, Inc. (the "Issuer"), MediPacific, Inc. ("Parent") and MediPacific Sub, Inc. ("Purchaser"), a wholly-owned subsidiary of Parent, pursuant to which Purchaser completed a tender offer (the "Offer") for shares of the Issuer, $0.0001 par value per share, and thereafter merged with and into the Issuer (the "Merger") effective as of August 31, 2023 (the "Effective Time"). In accordance with the terms of the Merger Agreement, at the Effective Time, the 16,813,146 shares beneficially owned by the Reporting Persons were automatically cancelled for no consideration.

F2: Consisted of shares beneficially owned by FS Development Holdings II, LLC, Foresite Capital Management V, LLC, Foresite Capital Opportunity Fund V, L.P., Foresite Capital Opportunity Management V, LLC and Foresite Capital Fund V, L.P., and of which Dr. Tananbaum may be deemed to have had a pecuniary interest.

F3: At the Effective Time, Merger Sub merged with and into the Issuer pursuant to Section 251(h) of the Delaware General Corporation Law, and each share of common stock of Merger Sub issued and outstanding immediately before the Effective Time automatically converted into and became one share of common stock, par value $0.0001 of the Issuer (representing 1,000 shares in the aggregate), with the Issuer surviving as a wholly owned subsidiary of Parent.

F4: The shares are beneficially owned by Parent. Parent is wholly owned by Foresite Capital Opportunity Fund V, L.P. Dr. Tananbaum is the managing member of Foresite Capital Opportunity Management V, LLC, which is the general partner of Foresite Capital Opportunity Fund V, L.P. Dr. Tananbaum may be deemed to have a pecuniary interest in the shares beneficially owned by Parent.

F5: On July 16, 2023, the Issuer's Board of Directors vested in full each option to purchase shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested as of that date. As of the Effective Time, each in-the-money Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled in-the-money Company Stock Option was entitled to receive, in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings and without interest) equal to the product of (x) the total number of shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess of $2.13 over the applicable exercise price per share under such Company Stock Option and (ii) one contingent value right for each share subject thereto.

F6: On July 16, 2023, the Issuer's Board of Directors vested in full each unvested Company Stock Option. Pursuant to the Merger Agreement, each Company Stock Option that was not in the money as of the Effective Time was cancelled for no consideration at the Effective Time.

Theseus Pharmaceuticals, Inc.

Report date July 17, 2023 · Filed July 19, 2023

Jointly reported with Foresite Capital Fund V, L.P., Foresite Capital Opportunity Fund V, L.P., Foresite Capital Opportunity Management V, LLC, Tananbaum James B.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee Footnote	4,108,796	Reported balance After 2023-07-17 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2023-07-17 · Purchase · Acquired 523,450 · Balance 4,108,796 F1: The shares are owned directly by Foresite Capital Fund V, L.P. ("Fund V"). Foresite Capital Management V, LLC ("FCM V") is the general partner of Fund V and may be deemed to have sole voting and dispositive power over these shares. James B. Tananbaum ("Dr. Tananbaum") is the sole managing member of FCM V and may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM V and Dr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM V or Dr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	1,385,825	Reported balance After 2023-07-17 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2023-07-17 · Purchase · Acquired 176,550 · Balance 1,385,825 F2: The shares are owned directly by Foresite Capital Opportunity Fund V, L.P. ("Opportunity Fund V"). Foresite Capital Opportunity Management V, LLC ("FCOM V") is the general partner of Opportunity Fund V and may be deemed to have sole voting and dispositive power over these shares. Dr. Tananbaum is the sole managing member of FCOM V and may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCOM V and Dr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCOM V or Dr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose.

Filing footnotes · ownership attribution and instrument terms

F1: The shares are owned directly by Foresite Capital Fund V, L.P. ("Fund V"). Foresite Capital Management V, LLC ("FCM V") is the general partner of Fund V and may be deemed to have sole voting and dispositive power over these shares. James B. Tananbaum ("Dr. Tananbaum") is the sole managing member of FCM V and may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM V and Dr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM V or Dr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose.

F2: The shares are owned directly by Foresite Capital Opportunity Fund V, L.P. ("Opportunity Fund V"). Foresite Capital Opportunity Management V, LLC ("FCOM V") is the general partner of Opportunity Fund V and may be deemed to have sole voting and dispositive power over these shares. Dr. Tananbaum is the sole managing member of FCOM V and may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCOM V and Dr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCOM V or Dr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose.

Past disclosures · reporting ended (3)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Aclaris Therapeutics, Inc.

Report date November 01, 2021 · Filed November 03, 2021

Jointly reported with Foresite Capital Management III, LLC, Foresite Capital Fund III, L.P., Foresite Capital Management IV, LLC, Foresite Capital Fund IV, L.P., Foresite Capital Fund V, L.P., Tananbaum James B.

Section 16 reporting ended · disclosed 2021-11-03. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee Footnote	0	Reported balance After 2021-11-01 transaction · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · 2021-11-01 · Other · Disposed 1,954,904 · Balance 0 F1: On November 1, 2021, Foresite Capital Fund III, L.P. ("Fund III") distributed, for no consideration, 1,954,904 shares of the Issuer's Common Stock (the "Fund III Shares") to its limited partners and to Foresite Capital Management III, LLC ("FCM III"), the general partner of Fund III, representing each such partner's pro rata interest in such Fund III Shares. On the same date, FCM III distributed, for no consideration, the Fund III Shares it received in the distribution by Fund III to its members, representing each such member's pro rata interest in such Fund III Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and/or 16a-9 of the Securities Exchange Act of 1934, as amended. F2: The shares are owned directly by Fund III. FCM III is the general partner of Fund III, may be deemed to have sole voting and dispositive power over these shares. James B. Tananbaum ("Mr. Tananbaum") is the sole managing member of FCM III and may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM III and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM III or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	8,276	Reported balance After 2021-11-01 transaction · row 4 Holding and transaction disclosures are not merged. 1 source row Row 4 · 2021-11-01 · Other · Acquired 8,276 · Balance 8,276 F5: Represents shares received by the James B. Tananbaum and Dana Shonfeld Tananbaum Family Trust pursuant to pro rata distributions by Fund III and FCM III, for no consideration, of shares of the Issuer's Common Stock to their respective partners or members, as applicable. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and/or 16a-9 of the Securities Exchange Act of 1934, as amended. F6: These shares are held of record by a family trust for which Mr. Tananbaum is a trustee. Each of the Reporting Persons disclaims the existence of a "group" and, other than Mr. Tananbaum, disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that any such person is the beneficial owner of such securities, except to the extent of such person's pecuniary interest therein, if any.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	3,399,034	Reported balance Holding disclosure · report date 2021-11-01 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 3,399,034 F3: The shares are owned directly by Foresite Capital Fund IV, L.P. ("Fund IV"). Foresite Capital Management IV, LLC ("FCM IV") is the general partner of Fund IV and may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum is the sole managing member of FCM IV and may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM IV and Mr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM IV or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	1,258,243	Reported balance Holding disclosure · report date 2021-11-01 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 1,258,243 F4: The shares are owned directly by Foresite Capital Fund V, L.P. ("Fund V"). Foresite Capital Management V, LLC ("FCM V") is the general partner of Fund V and may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum is the sole managing member of FCM V and may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM V and Mr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM V or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose.

Filing footnotes · ownership attribution and instrument terms

F1: On November 1, 2021, Foresite Capital Fund III, L.P. ("Fund III") distributed, for no consideration, 1,954,904 shares of the Issuer's Common Stock (the "Fund III Shares") to its limited partners and to Foresite Capital Management III, LLC ("FCM III"), the general partner of Fund III, representing each such partner's pro rata interest in such Fund III Shares. On the same date, FCM III distributed, for no consideration, the Fund III Shares it received in the distribution by Fund III to its members, representing each such member's pro rata interest in such Fund III Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and/or 16a-9 of the Securities Exchange Act of 1934, as amended.

F2: The shares are owned directly by Fund III. FCM III is the general partner of Fund III, may be deemed to have sole voting and dispositive power over these shares. James B. Tananbaum ("Mr. Tananbaum") is the sole managing member of FCM III and may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM III and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM III or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose.

F3: The shares are owned directly by Foresite Capital Fund IV, L.P. ("Fund IV"). Foresite Capital Management IV, LLC ("FCM IV") is the general partner of Fund IV and may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum is the sole managing member of FCM IV and may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM IV and Mr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM IV or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose.

F4: The shares are owned directly by Foresite Capital Fund V, L.P. ("Fund V"). Foresite Capital Management V, LLC ("FCM V") is the general partner of Fund V and may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum is the sole managing member of FCM V and may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM V and Mr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM V or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose.

F5: Represents shares received by the James B. Tananbaum and Dana Shonfeld Tananbaum Family Trust pursuant to pro rata distributions by Fund III and FCM III, for no consideration, of shares of the Issuer's Common Stock to their respective partners or members, as applicable. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and/or 16a-9 of the Securities Exchange Act of 1934, as amended.

F6: These shares are held of record by a family trust for which Mr. Tananbaum is a trustee. Each of the Reporting Persons disclaims the existence of a "group" and, other than Mr. Tananbaum, disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that any such person is the beneficial owner of such securities, except to the extent of such person's pecuniary interest therein, if any.

Eikon Therapeutics, Inc.

Report date February 04, 2026 · Filed February 06, 2026

Jointly reported with Foresite Capital Management IV, LLC, Foresite Capital Fund IV, L.P., Foresite Capital Fund V, L.P., Foresite Capital Opportunity Management V, LLC, Foresite Capital Opportunity Fund V, L.P., Foresite Capital VI-A Management, LLC, Foresite Capital VI-A, LLC

Section 16 reporting ended · disclosed 2026-02-06. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee Footnote	1,340,878	Reported balance After 2026-02-04 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2026-02-04 · Conversion · Acquired 1,340,878 · Balance 1,340,878 F1: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F2: The shares are held of record by Foresite Capital Fund IV, L.P. ("Fund IV"). Foresite Capital Management IV, LLC ("FCM IV") is the general partner of Fund IV and may be deemed to have sole voting and dispositive power over such shares. James B. Tananbaum ("Tananbaum"), the managing member of FCM IV, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and, other than Fund IV, disclaims beneficial ownership of the shares held by Fund IV, except to the extent of such person's pecuniary interest in such securities.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	1,676,399	Reported balance After 2026-02-04 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2026-02-04 · Conversion · Acquired 335,521 · Balance 1,676,399 F1: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F2: The shares are held of record by Foresite Capital Fund IV, L.P. ("Fund IV"). Foresite Capital Management IV, LLC ("FCM IV") is the general partner of Fund IV and may be deemed to have sole voting and dispositive power over such shares. James B. Tananbaum ("Tananbaum"), the managing member of FCM IV, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and, other than Fund IV, disclaims beneficial ownership of the shares held by Fund IV, except to the extent of such person's pecuniary interest in such securities.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	1,714,254	Reported balance After 2026-02-04 transaction · row 3 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 3 · 2026-02-04 · Conversion · Acquired 37,855 · Balance 1,714,254 F1: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F2: The shares are held of record by Foresite Capital Fund IV, L.P. ("Fund IV"). Foresite Capital Management IV, LLC ("FCM IV") is the general partner of Fund IV and may be deemed to have sole voting and dispositive power over such shares. James B. Tananbaum ("Tananbaum"), the managing member of FCM IV, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and, other than Fund IV, disclaims beneficial ownership of the shares held by Fund IV, except to the extent of such person's pecuniary interest in such securities.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	1,943,682	Reported balance After 2026-02-04 transaction · row 4 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 4 · 2026-02-04 · Conversion · Acquired 229,428 · Balance 1,943,682 F1: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F2: The shares are held of record by Foresite Capital Fund IV, L.P. ("Fund IV"). Foresite Capital Management IV, LLC ("FCM IV") is the general partner of Fund IV and may be deemed to have sole voting and dispositive power over such shares. James B. Tananbaum ("Tananbaum"), the managing member of FCM IV, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and, other than Fund IV, disclaims beneficial ownership of the shares held by Fund IV, except to the extent of such person's pecuniary interest in such securities.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	697,885	Reported balance After 2026-02-04 transaction · row 5 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 5 · 2026-02-04 · Conversion · Acquired 697,885 · Balance 697,885 F1: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F3: The shares are held of record by Foresite Capital Fund V, L.P. ("Fund V"). Foresite Capital Management V, LLC ("FCM V") is the general partner of Fund V and may be deemed to have sole voting and dispositive power over such shares. James B. Tananbaum ("Tananbaum"), the managing member of FCM V, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and, other than Fund V, disclaims beneficial ownership of the shares held by Fund V, except to the extent of such person's pecuniary interest in such securities.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	735,740	Reported balance After 2026-02-04 transaction · row 6 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 6 · 2026-02-04 · Conversion · Acquired 37,855 · Balance 735,740 F1: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F3: The shares are held of record by Foresite Capital Fund V, L.P. ("Fund V"). Foresite Capital Management V, LLC ("FCM V") is the general partner of Fund V and may be deemed to have sole voting and dispositive power over such shares. James B. Tananbaum ("Tananbaum"), the managing member of FCM V, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and, other than Fund V, disclaims beneficial ownership of the shares held by Fund V, except to the extent of such person's pecuniary interest in such securities.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	737,366	Reported balance After 2026-02-04 transaction · row 7 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 7 · 2026-02-04 · Conversion · Acquired 1,626 · Balance 737,366 F1: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F3: The shares are held of record by Foresite Capital Fund V, L.P. ("Fund V"). Foresite Capital Management V, LLC ("FCM V") is the general partner of Fund V and may be deemed to have sole voting and dispositive power over such shares. James B. Tananbaum ("Tananbaum"), the managing member of FCM V, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and, other than Fund V, disclaims beneficial ownership of the shares held by Fund V, except to the extent of such person's pecuniary interest in such securities.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	804,573	Reported balance After 2026-02-04 transaction · row 8 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 8 · 2026-02-04 · Conversion · Acquired 67,207 · Balance 804,573 F1: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F3: The shares are held of record by Foresite Capital Fund V, L.P. ("Fund V"). Foresite Capital Management V, LLC ("FCM V") is the general partner of Fund V and may be deemed to have sole voting and dispositive power over such shares. James B. Tananbaum ("Tananbaum"), the managing member of FCM V, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and, other than Fund V, disclaims beneficial ownership of the shares held by Fund V, except to the extent of such person's pecuniary interest in such securities.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	1,263,428	Reported balance After 2026-02-04 transaction · row 9 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 9 · 2026-02-04 · Conversion · Acquired 458,855 · Balance 1,263,428 F1: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F3: The shares are held of record by Foresite Capital Fund V, L.P. ("Fund V"). Foresite Capital Management V, LLC ("FCM V") is the general partner of Fund V and may be deemed to have sole voting and dispositive power over such shares. James B. Tananbaum ("Tananbaum"), the managing member of FCM V, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and, other than Fund V, disclaims beneficial ownership of the shares held by Fund V, except to the extent of such person's pecuniary interest in such securities.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	348,942	Reported balance After 2026-02-04 transaction · row 10 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 10 · 2026-02-04 · Conversion · Acquired 348,942 · Balance 348,942 F1: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F4: The shares are held of record by Foresite Capital Opportunity Fund V, L.P. ("Opportunity Fund V"). Foresite Capital Opportunity Management V, LLC ("FCOM V") is the general partner of Opportunity Fund V and may be deemed to have sole voting and dispositive power over such shares. Tananbaum, the managing member of FCOM V, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Exchange Act, and, other than Opportunity Fund V, disclaims beneficial ownership of the shares held by Opportunity Fund V, except to the extent of such person's pecuniary interest in such securities.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	386,797	Reported balance After 2026-02-04 transaction · row 11 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 11 · 2026-02-04 · Conversion · Acquired 37,855 · Balance 386,797 F1: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F4: The shares are held of record by Foresite Capital Opportunity Fund V, L.P. ("Opportunity Fund V"). Foresite Capital Opportunity Management V, LLC ("FCOM V") is the general partner of Opportunity Fund V and may be deemed to have sole voting and dispositive power over such shares. Tananbaum, the managing member of FCOM V, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Exchange Act, and, other than Opportunity Fund V, disclaims beneficial ownership of the shares held by Opportunity Fund V, except to the extent of such person's pecuniary interest in such securities.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	387,719	Reported balance After 2026-02-04 transaction · row 12 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 12 · 2026-02-04 · Conversion · Acquired 922 · Balance 387,719 F1: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F4: The shares are held of record by Foresite Capital Opportunity Fund V, L.P. ("Opportunity Fund V"). Foresite Capital Opportunity Management V, LLC ("FCOM V") is the general partner of Opportunity Fund V and may be deemed to have sole voting and dispositive power over such shares. Tananbaum, the managing member of FCOM V, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Exchange Act, and, other than Opportunity Fund V, disclaims beneficial ownership of the shares held by Opportunity Fund V, except to the extent of such person's pecuniary interest in such securities.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	425,852	Reported balance After 2026-02-04 transaction · row 13 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 13 · 2026-02-04 · Conversion · Acquired 38,133 · Balance 425,852 F1: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F4: The shares are held of record by Foresite Capital Opportunity Fund V, L.P. ("Opportunity Fund V"). Foresite Capital Opportunity Management V, LLC ("FCOM V") is the general partner of Opportunity Fund V and may be deemed to have sole voting and dispositive power over such shares. Tananbaum, the managing member of FCOM V, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Exchange Act, and, other than Opportunity Fund V, disclaims beneficial ownership of the shares held by Opportunity Fund V, except to the extent of such person's pecuniary interest in such securities.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	408,725	Reported balance After 2026-02-04 transaction · row 14 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 14 · 2026-02-04 · Conversion · Acquired 408,725 · Balance 408,725 F1: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F5: The shares are held of record by Foresite Capital VI-A, LLC ("Fund VI-A"). Foresite Capital VI-A Management, LLC ("FC VI-A Management") is the general partner of Fund VI-A and may be deemed to have sole voting and dispositive power over such shares. Tananbaum, the managing member of FC VI-A Management, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Exchange Act, and, other than Fund VI-A, disclaims beneficial ownership of the shares held by Fund VI-A, except to the extent of such person's pecuniary interest in such securities.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	1,318,983	Reported balance After 2026-02-04 transaction · row 15 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 15 · 2026-02-04 · Purchase · Acquired 55,555 · Balance 1,318,983 F3: The shares are held of record by Foresite Capital Fund V, L.P. ("Fund V"). Foresite Capital Management V, LLC ("FCM V") is the general partner of Fund V and may be deemed to have sole voting and dispositive power over such shares. James B. Tananbaum ("Tananbaum"), the managing member of FCM V, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and, other than Fund V, disclaims beneficial ownership of the shares held by Fund V, except to the extent of such person's pecuniary interest in such securities.
Series A Preferred StockSEC Table II · derivative / convertible security	IndirectSee Footnote	0	Reported balance After 2026-02-04 transaction · row 16 Instrument identity requires review; Table II rows are not merged. 1 source row Row 16 · 2026-02-04 · Conversion · Disposed 10,000,000 · Balance 0 F1: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F2: The shares are held of record by Foresite Capital Fund IV, L.P. ("Fund IV"). Foresite Capital Management IV, LLC ("FCM IV") is the general partner of Fund IV and may be deemed to have sole voting and dispositive power over such shares. James B. Tananbaum ("Tananbaum"), the managing member of FCM IV, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and, other than Fund IV, disclaims beneficial ownership of the shares held by Fund IV, except to the extent of such person's pecuniary interest in such securities.
Series A-1 Preferred StockSEC Table II · derivative / convertible security	IndirectSee Footnote	0	Reported balance After 2026-02-04 transaction · row 17 Instrument identity requires review; Table II rows are not merged. 1 source row Row 17 · 2026-02-04 · Conversion · Disposed 2,502,252 · Balance 0 F1: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F2: The shares are held of record by Foresite Capital Fund IV, L.P. ("Fund IV"). Foresite Capital Management IV, LLC ("FCM IV") is the general partner of Fund IV and may be deemed to have sole voting and dispositive power over such shares. James B. Tananbaum ("Tananbaum"), the managing member of FCM IV, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and, other than Fund IV, disclaims beneficial ownership of the shares held by Fund IV, except to the extent of such person's pecuniary interest in such securities.
Series A-1 Preferred StockSEC Table II · derivative / convertible security	IndirectSee Footnote	0	Reported balance After 2026-02-04 transaction · row 18 Instrument identity requires review; Table II rows are not merged. 1 source row Row 18 · 2026-02-04 · Conversion · Disposed 5,204,684 · Balance 0 F1: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F3: The shares are held of record by Foresite Capital Fund V, L.P. ("Fund V"). Foresite Capital Management V, LLC ("FCM V") is the general partner of Fund V and may be deemed to have sole voting and dispositive power over such shares. James B. Tananbaum ("Tananbaum"), the managing member of FCM V, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and, other than Fund V, disclaims beneficial ownership of the shares held by Fund V, except to the extent of such person's pecuniary interest in such securities.
Series A-1 Preferred StockSEC Table II · derivative / convertible security	IndirectSee Footnote	0	Reported balance After 2026-02-04 transaction · row 19 Instrument identity requires review; Table II rows are not merged. 1 source row Row 19 · 2026-02-04 · Conversion · Disposed 2,602,342 · Balance 0 F1: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F4: The shares are held of record by Foresite Capital Opportunity Fund V, L.P. ("Opportunity Fund V"). Foresite Capital Opportunity Management V, LLC ("FCOM V") is the general partner of Opportunity Fund V and may be deemed to have sole voting and dispositive power over such shares. Tananbaum, the managing member of FCOM V, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Exchange Act, and, other than Opportunity Fund V, disclaims beneficial ownership of the shares held by Opportunity Fund V, except to the extent of such person's pecuniary interest in such securities.
Series B-1 Preferred StockSEC Table II · derivative / convertible security	IndirectSee Footnote	0	Reported balance After 2026-02-04 transaction · row 20 Instrument identity requires review; Table II rows are not merged. 1 source row Row 20 · 2026-02-04 · Conversion · Disposed 282,317 · Balance 0 F1: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F2: The shares are held of record by Foresite Capital Fund IV, L.P. ("Fund IV"). Foresite Capital Management IV, LLC ("FCM IV") is the general partner of Fund IV and may be deemed to have sole voting and dispositive power over such shares. James B. Tananbaum ("Tananbaum"), the managing member of FCM IV, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and, other than Fund IV, disclaims beneficial ownership of the shares held by Fund IV, except to the extent of such person's pecuniary interest in such securities.
Series B-1 Preferred StockSEC Table II · derivative / convertible security	IndirectSee Footnote	0	Reported balance After 2026-02-04 transaction · row 21 Instrument identity requires review; Table II rows are not merged. 1 source row Row 21 · 2026-02-04 · Conversion · Disposed 282,317 · Balance 0 F1: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F3: The shares are held of record by Foresite Capital Fund V, L.P. ("Fund V"). Foresite Capital Management V, LLC ("FCM V") is the general partner of Fund V and may be deemed to have sole voting and dispositive power over such shares. James B. Tananbaum ("Tananbaum"), the managing member of FCM V, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and, other than Fund V, disclaims beneficial ownership of the shares held by Fund V, except to the extent of such person's pecuniary interest in such securities.
Series B-1 Preferred StockSEC Table II · derivative / convertible security	IndirectSee Footnote	0	Reported balance After 2026-02-04 transaction · row 22 Instrument identity requires review; Table II rows are not merged. 1 source row Row 22 · 2026-02-04 · Conversion · Disposed 282,317 · Balance 0 F1: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F4: The shares are held of record by Foresite Capital Opportunity Fund V, L.P. ("Opportunity Fund V"). Foresite Capital Opportunity Management V, LLC ("FCOM V") is the general partner of Opportunity Fund V and may be deemed to have sole voting and dispositive power over such shares. Tananbaum, the managing member of FCOM V, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Exchange Act, and, other than Opportunity Fund V, disclaims beneficial ownership of the shares held by Opportunity Fund V, except to the extent of such person's pecuniary interest in such securities.
Series B-1 Preferred StockSEC Table II · derivative / convertible security	IndirectSee Footnote	0	Reported balance After 2026-02-04 transaction · row 23 Instrument identity requires review; Table II rows are not merged. 1 source row Row 23 · 2026-02-04 · Conversion · Disposed 3,048,192 · Balance 0 F1: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F5: The shares are held of record by Foresite Capital VI-A, LLC ("Fund VI-A"). Foresite Capital VI-A Management, LLC ("FC VI-A Management") is the general partner of Fund VI-A and may be deemed to have sole voting and dispositive power over such shares. Tananbaum, the managing member of FC VI-A Management, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Exchange Act, and, other than Fund VI-A, disclaims beneficial ownership of the shares held by Fund VI-A, except to the extent of such person's pecuniary interest in such securities.
Series C Preferred StockSEC Table II · derivative / convertible security	IndirectSee Footnote	0	Reported balance After 2026-02-04 transaction · row 24 Instrument identity requires review; Table II rows are not merged. 1 source row Row 24 · 2026-02-04 · Conversion · Disposed 12,123 · Balance 0 F1: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F3: The shares are held of record by Foresite Capital Fund V, L.P. ("Fund V"). Foresite Capital Management V, LLC ("FCM V") is the general partner of Fund V and may be deemed to have sole voting and dispositive power over such shares. James B. Tananbaum ("Tananbaum"), the managing member of FCM V, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and, other than Fund V, disclaims beneficial ownership of the shares held by Fund V, except to the extent of such person's pecuniary interest in such securities.
Series C Preferred StockSEC Table II · derivative / convertible security	IndirectSee Footnote	0	Reported balance After 2026-02-04 transaction · row 25 Instrument identity requires review; Table II rows are not merged. 1 source row Row 25 · 2026-02-04 · Conversion · Disposed 6,878 · Balance 0 F1: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F4: The shares are held of record by Foresite Capital Opportunity Fund V, L.P. ("Opportunity Fund V"). Foresite Capital Opportunity Management V, LLC ("FCOM V") is the general partner of Opportunity Fund V and may be deemed to have sole voting and dispositive power over such shares. Tananbaum, the managing member of FCOM V, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Exchange Act, and, other than Opportunity Fund V, disclaims beneficial ownership of the shares held by Opportunity Fund V, except to the extent of such person's pecuniary interest in such securities.
Series C-1 Preferred StockSEC Table II · derivative / convertible security	IndirectSee Footnote	0	Reported balance After 2026-02-04 transaction · row 26 Instrument identity requires review; Table II rows are not merged. 1 source row Row 26 · 2026-02-04 · Conversion · Disposed 501,219 · Balance 0 F1: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F3: The shares are held of record by Foresite Capital Fund V, L.P. ("Fund V"). Foresite Capital Management V, LLC ("FCM V") is the general partner of Fund V and may be deemed to have sole voting and dispositive power over such shares. James B. Tananbaum ("Tananbaum"), the managing member of FCM V, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and, other than Fund V, disclaims beneficial ownership of the shares held by Fund V, except to the extent of such person's pecuniary interest in such securities.
Series C-1 Preferred StockSEC Table II · derivative / convertible security	IndirectSee Footnote	0	Reported balance After 2026-02-04 transaction · row 27 Instrument identity requires review; Table II rows are not merged. 1 source row Row 27 · 2026-02-04 · Conversion · Disposed 284,392 · Balance 0 F1: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F4: The shares are held of record by Foresite Capital Opportunity Fund V, L.P. ("Opportunity Fund V"). Foresite Capital Opportunity Management V, LLC ("FCOM V") is the general partner of Opportunity Fund V and may be deemed to have sole voting and dispositive power over such shares. Tananbaum, the managing member of FCOM V, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Exchange Act, and, other than Opportunity Fund V, disclaims beneficial ownership of the shares held by Opportunity Fund V, except to the extent of such person's pecuniary interest in such securities.
Series D Preferred StockSEC Table II · derivative / convertible security	IndirectSee Footnote	0	Reported balance After 2026-02-04 transaction · row 28 Instrument identity requires review; Table II rows are not merged. 1 source row Row 28 · 2026-02-04 · Conversion · Disposed 1,711,025 · Balance 0 F1: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F2: The shares are held of record by Foresite Capital Fund IV, L.P. ("Fund IV"). Foresite Capital Management IV, LLC ("FCM IV") is the general partner of Fund IV and may be deemed to have sole voting and dispositive power over such shares. James B. Tananbaum ("Tananbaum"), the managing member of FCM IV, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and, other than Fund IV, disclaims beneficial ownership of the shares held by Fund IV, except to the extent of such person's pecuniary interest in such securities.
Series D Preferred StockSEC Table II · derivative / convertible security	IndirectSee Footnote	0	Reported balance After 2026-02-04 transaction · row 29 Instrument identity requires review; Table II rows are not merged. 1 source row Row 29 · 2026-02-04 · Conversion · Disposed 3,422,051 · Balance 0 F1: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F3: The shares are held of record by Foresite Capital Fund V, L.P. ("Fund V"). Foresite Capital Management V, LLC ("FCM V") is the general partner of Fund V and may be deemed to have sole voting and dispositive power over such shares. James B. Tananbaum ("Tananbaum"), the managing member of FCM V, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and, other than Fund V, disclaims beneficial ownership of the shares held by Fund V, except to the extent of such person's pecuniary interest in such securities.
WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $43.59 · Expires 2030-02-14	IndirectSee Footnote	17,092	Reported balance Holding disclosure · report date 2026-02-04 · row 30 Instrument identity requires review; Table II rows are not merged. 1 source row Row 30 · Balance 17,092 F2: The shares are held of record by Foresite Capital Fund IV, L.P. ("Fund IV"). Foresite Capital Management IV, LLC ("FCM IV") is the general partner of Fund IV and may be deemed to have sole voting and dispositive power over such shares. James B. Tananbaum ("Tananbaum"), the managing member of FCM IV, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and, other than Fund IV, disclaims beneficial ownership of the shares held by Fund IV, except to the extent of such person's pecuniary interest in such securities.
WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $43.59 · Expires 2030-02-14	IndirectSee Footnote	34,185	Reported balance Holding disclosure · report date 2026-02-04 · row 31 Instrument identity requires review; Table II rows are not merged. 1 source row Row 31 · Balance 34,185 F3: The shares are held of record by Foresite Capital Fund V, L.P. ("Fund V"). Foresite Capital Management V, LLC ("FCM V") is the general partner of Fund V and may be deemed to have sole voting and dispositive power over such shares. James B. Tananbaum ("Tananbaum"), the managing member of FCM V, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and, other than Fund V, disclaims beneficial ownership of the shares held by Fund V, except to the extent of such person's pecuniary interest in such securities.

Filing footnotes · ownership attribution and instrument terms

F1: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date.

F2: The shares are held of record by Foresite Capital Fund IV, L.P. ("Fund IV"). Foresite Capital Management IV, LLC ("FCM IV") is the general partner of Fund IV and may be deemed to have sole voting and dispositive power over such shares. James B. Tananbaum ("Tananbaum"), the managing member of FCM IV, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and, other than Fund IV, disclaims beneficial ownership of the shares held by Fund IV, except to the extent of such person's pecuniary interest in such securities.

F3: The shares are held of record by Foresite Capital Fund V, L.P. ("Fund V"). Foresite Capital Management V, LLC ("FCM V") is the general partner of Fund V and may be deemed to have sole voting and dispositive power over such shares. James B. Tananbaum ("Tananbaum"), the managing member of FCM V, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and, other than Fund V, disclaims beneficial ownership of the shares held by Fund V, except to the extent of such person's pecuniary interest in such securities.

F4: The shares are held of record by Foresite Capital Opportunity Fund V, L.P. ("Opportunity Fund V"). Foresite Capital Opportunity Management V, LLC ("FCOM V") is the general partner of Opportunity Fund V and may be deemed to have sole voting and dispositive power over such shares. Tananbaum, the managing member of FCOM V, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Exchange Act, and, other than Opportunity Fund V, disclaims beneficial ownership of the shares held by Opportunity Fund V, except to the extent of such person's pecuniary interest in such securities.

F5: The shares are held of record by Foresite Capital VI-A, LLC ("Fund VI-A"). Foresite Capital VI-A Management, LLC ("FC VI-A Management") is the general partner of Fund VI-A and may be deemed to have sole voting and dispositive power over such shares. Tananbaum, the managing member of FC VI-A Management, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Exchange Act, and, other than Fund VI-A, disclaims beneficial ownership of the shares held by Fund VI-A, except to the extent of such person's pecuniary interest in such securities.

Kinnate Biopharma Inc.

Report date April 03, 2024 · Filed April 05, 2024

Section 16 reporting ended · disclosed 2024-04-05. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee Footnote	Reported balance After 2024-04-03 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2024-04-03 · Disposition to issuer · Disposed 9,671,643 · Balance 0 F1: Disposed of pursuant to that certain Agreement and Plan of Merger, dated February 16, 2024, by and between the Issuer, XOMA Corporation and XRA 1 Corp. in exchange for (i) $2.5879 in cash per share, plus (ii) one non-transferable contingent value right per share. F2: The shares are owned directly by Foresite Capital Fund IV, L.P. ("Fund IV"). Foresite Capital Management IV, LLC ("FCM IV") is the general partner of Fund IV and may be deemed to have sole voting and dispositive power over these shares. James B. Tananbaum ("Dr. Tananbaum"), in his capacity as the sole managing member of FCM IV, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM IV and Dr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM IV or Dr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	Reported balance After 2024-04-03 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2024-04-03 · Disposition to issuer · Disposed 3,525,957 · Balance 0 F1: Disposed of pursuant to that certain Agreement and Plan of Merger, dated February 16, 2024, by and between the Issuer, XOMA Corporation and XRA 1 Corp. in exchange for (i) $2.5879 in cash per share, plus (ii) one non-transferable contingent value right per share. F3: The shares are owned directly by Foresite Capital Fund V, L.P. ("Fund V"). Foresite Capital Management V, LLC ("FCM V") is the general partner of Fund V and may be deemed to have sole voting and dispositive power over these shares. Dr. Tananbaum is the sole managing member of FCM V and may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM V and Dr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM V or Dr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	Reported balance After 2024-04-03 transaction · row 3 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 3 · 2024-04-03 · Disposition to issuer · Disposed 520,711 · Balance 0 F1: Disposed of pursuant to that certain Agreement and Plan of Merger, dated February 16, 2024, by and between the Issuer, XOMA Corporation and XRA 1 Corp. in exchange for (i) $2.5879 in cash per share, plus (ii) one non-transferable contingent value right per share. F4: The shares are owned directly by Foresite Capital Opportunity Fund V, L.P. ("Opportunity Fund V"). Foresite Capital Opportunity Management V, LLC ("FCOM V") is the general partner of Opportunity Fund V and may be deemed to have sole voting and dispositive power over these shares. Dr. Tananbaum is the sole managing member of FCOM V and may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCOM V and Dr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCOM V or Dr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose.

Filing footnotes · ownership attribution and instrument terms

F1: Disposed of pursuant to that certain Agreement and Plan of Merger, dated February 16, 2024, by and between the Issuer, XOMA Corporation and XRA 1 Corp. in exchange for (i) $2.5879 in cash per share, plus (ii) one non-transferable contingent value right per share.

F2: The shares are owned directly by Foresite Capital Fund IV, L.P. ("Fund IV"). Foresite Capital Management IV, LLC ("FCM IV") is the general partner of Fund IV and may be deemed to have sole voting and dispositive power over these shares. James B. Tananbaum ("Dr. Tananbaum"), in his capacity as the sole managing member of FCM IV, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM IV and Dr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM IV or Dr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose.

F3: The shares are owned directly by Foresite Capital Fund V, L.P. ("Fund V"). Foresite Capital Management V, LLC ("FCM V") is the general partner of Fund V and may be deemed to have sole voting and dispositive power over these shares. Dr. Tananbaum is the sole managing member of FCM V and may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM V and Dr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM V or Dr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose.

F4: The shares are owned directly by Foresite Capital Opportunity Fund V, L.P. ("Opportunity Fund V"). Foresite Capital Opportunity Management V, LLC ("FCOM V") is the general partner of Opportunity Fund V and may be deemed to have sole voting and dispositive power over these shares. Dr. Tananbaum is the sole managing member of FCOM V and may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCOM V and Dr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCOM V or Dr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
May 08, 2023 Filed May 10, 2023 17:42 UTC	Kinnate Biopharma Inc. KNTE · Entity 92187	PurchaseCommon Stock	1,550,956	$2.80	$4,342,676.80	Disclosure SEC source: 0001209191-23-028527 · doc4.xml · nonDerivative · entry 1 Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner Foresite Capital Fund V, L.P. · CIK 0001792204 · 10% owner Foresite Capital Management V, LLC · CIK 0001792206 · 10% owner Foresite Capital Opportunity Fund V, L.P. · CIK 0001792205 · 10% owner Foresite Capital Opportunity Management V, LLC · CIK 0001792207 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 3,525,957 F1 · ownership.nature: The shares are owned directly by Foresite Capital Fund V, L.P. ("Fund V"). Foresite Capital Management V, LLC ("FCM V") is the general partner of Fund V and may be deemed to have sole voting and dispositive power over these shares. James B. Tananbaum ("Dr. Tananbaum") is the sole managing member of FCM V and may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM V and Dr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM V or Dr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document
April 05, 2023 Filed Apr 7, 2023 01:08 UTC	PARDES BIOSCIENCES, INC. PRDS · Entity 110063	PurchaseCommon Stock	773,952	$1.50	$1,160,928.00	Disclosure SEC source: 0001213900-23-028116 · ownership.xml · nonDerivative · entry 1 Foresite Capital Management V, LLC · CIK 0001792206 · 10% owner Foresite Capital Fund V, L.P. · CIK 0001792204 · 10% owner Tananbaum James B. · CIK 0001581754 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 13,583,762 F1 · ownership.nature: On April 5, 2023, Foresite Capital Fund V, L.P. ("Capital Fund V L.P.") purchased 773,952 shares of the Issuer's Common Stock at an aggregate price of approximately $1.50 per share, or $1,160,928 in the aggregate, in open market purchases. Foresite Capital Management V, LLC ("FCMVLLC") is the general partner of Capital Fund V L.P. Each of FCMVLLC and Dr. Tananbaum, in his capacity as managing member of FCMVLLC, disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein. Read SEC document
February 17, 2023 Filed Feb 22, 2023 14:49 UTC	Kinnate Biopharma Inc. KNTE · Entity 92187	OtherCommon Stock	1,100,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-23-011565 · doc4.xml · nonDerivative · entry 1 Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner Foresite Capital Fund V, L.P. · CIK 0001792204 · 10% owner Foresite Capital Management V, LLC · CIK 0001792206 · 10% owner Foresite Capital Opportunity Fund V, L.P. · CIK 0001792205 · 10% owner Foresite Capital Opportunity Management V, LLC · CIK 0001792207 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,975,001 F1 · kind: On February 17, 2023, the Issuer completed the acquisition of Kinnjiu Biompharma, Inc. (the "Kinnjiu Acquisition"). Foresite Capital Fund V, L.P. ("Fund V") was a shareholder of Kinnjiu Biompharma, Inc. and, as a result of the Kinnjiu Acquisition, Fund V received a combination of cash and 1,100,000 shares of the Issuer's Common Stock. F2 · shares: Received in exchange for 17,500,000 shares of Kinnjiu Biopharma, Inc. in connection with the Kinnjiu Acquisition. The number of shares received was determined based on a volume weighted average price per share of $6.7757. F2 · price: Received in exchange for 17,500,000 shares of Kinnjiu Biopharma, Inc. in connection with the Kinnjiu Acquisition. The number of shares received was determined based on a volume weighted average price per share of $6.7757. F3 · ownership.nature: The shares are owned directly by Fund V. Foresite Capital Management V, LLC ("FCM V") is the general partner of Fund V and may be deemed to have sole voting and dispositive power over these shares. James B. Tananbaum ("Dr. Tananbaum") is the sole managing member of FCM V and may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM V and Dr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM V or Dr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document
December 29, 2022 Filed Jan 3, 2023 16:24 UTC	Theseus Pharmaceuticals, Inc. THRX · Entity 94301	PurchaseCommon Stock	250,000	$5.00	$1,250,000.00	Disclosure SEC source: 0001209191-23-000204 · doc4.xml · nonDerivative · entry 2 Foresite Capital Management V, LLC · CIK 0001792206 · 10% owner Foresite Capital Fund V, L.P. · CIK 0001792204 · 10% owner Foresite Capital Opportunity Fund V, L.P. · CIK 0001792205 · 10% owner Foresite Capital Opportunity Management V, LLC · CIK 0001792207 · 10% owner Tananbaum James B. · CIK 0001581754 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,209,275 F2 · ownership.nature: The shares are owned directly by Foresite Capital Opportunity Fund V, L.P. ("Opportunity Fund V"). Foresite Capital Opportunity Management V, LLC ("FCOM V") is the general partner of Opportunity Fund V and may be deemed to have sole voting and dispositive power over these shares. Dr. Tananbaum is the sole managing member of FCOM V and may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCOM V and Dr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCOM V or Dr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document
December 29, 2022 Filed Jan 3, 2023 16:24 UTC	Theseus Pharmaceuticals, Inc. THRX · Entity 94301	PurchaseCommon Stock	250,000	$5.00	$1,250,000.00	Disclosure SEC source: 0001209191-23-000204 · doc4.xml · nonDerivative · entry 1 Foresite Capital Management V, LLC · CIK 0001792206 · 10% owner Foresite Capital Fund V, L.P. · CIK 0001792204 · 10% owner Foresite Capital Opportunity Fund V, L.P. · CIK 0001792205 · 10% owner Foresite Capital Opportunity Management V, LLC · CIK 0001792207 · 10% owner Tananbaum James B. · CIK 0001581754 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 3,585,346 F1 · ownership.nature: The shares are owned directly by Foresite Capital Fund V, L.P. ("Fund V"). Foresite Capital Management V, LLC ("FCM V") is the general partner of Fund V and may be deemed to have sole voting and dispositive power over these shares. James B. Tananbaum ("Dr. Tananbaum") is the sole managing member of FCM V and may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM V and Dr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM V or Dr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document
December 01, 2022 Filed Dec 5, 2022 21:24 UTC	PARDES BIOSCIENCES, INC. PRDS · Entity 110063	PurchaseCommon Stock	637,420	$0.85	$541,807.00	Disclosure SEC source: 0001213900-22-077637 · ownership.xml · nonDerivative · entry 1 Foresite Capital Management V, LLC · CIK 0001792206 · 10% owner Tananbaum James B. · CIK 0001581754 · Director · 10% owner Foresite Capital Fund V, L.P. · CIK 0001792204 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 12,809,810 F1 · ownership.nature: On December 1, 2022, Foresite Capital Fund V, L.P. ("Capital Fund V L.P.") purchased 637,420 shares of the Issuer's Common Stock at an aggregate price of approximately $0.85 per share, or $541,807 in the aggregate, in open market purchases. Foresite Capital Management V, LLC ("FCMVLLC") is the general partner of Capital Fund V L.P. Each of FCMVLLC and Dr. Tananbaum, in his capacity as managing member of FCMVLLC, disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein. Read SEC document
December 23, 2021 Filed Dec 28, 2021 21:30 UTC	PARDES BIOSCIENCES, INC. PRDS · Entity 110063	GrantStock Option (right to buy) · Derivative	75,000	$0.00 Strike: $9.80	$0.00	Disclosure SEC source: 0000899243-21-049928 · doc4.xml · derivative · entry 7 Tananbaum James B. · CIK 0001581754 · Director · 10% owner Foresite Capital Fund V, L.P. · CIK 0001792204 · 10% owner Foresite Capital Management V, LLC · CIK 0001792206 · 10% owner Foresite Capital Opportunity Fund V, L.P. · CIK 0001792205 · 10% owner Foresite Capital Opportunity Management V, LLC · CIK 0001792207 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2031-12-22 F5 · derivative.exercise_date: This option shall vest in substantially equal monthly installments over three years, subject to a continued service relationship. The vested shares subject to such option shall be exercisable upon the effectiveness of the Issuer's registration statement on Form S-8, registering the shares of the Issuer's 2021 Stock Option and Incentive Plan with the U.S. Securities and Exchange Commission Read SEC document
December 23, 2021 Filed Dec 28, 2021 21:30 UTC	PARDES BIOSCIENCES, INC. PRDS · Entity 110063	ConversionCommon Stock · Derivative	4,873,750	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0000899243-21-049928 · doc4.xml · derivative · entry 6 Tananbaum James B. · CIK 0001581754 · Director · 10% owner Foresite Capital Fund V, L.P. · CIK 0001792204 · 10% owner Foresite Capital Management V, LLC · CIK 0001792206 · 10% owner Foresite Capital Opportunity Fund V, L.P. · CIK 0001792205 · 10% owner Foresite Capital Opportunity Management V, LLC · CIK 0001792207 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 4,873,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: In connection with the closing of Pardes Biosciences, Inc.'s (formerly known as FS Development Corp. II) business combination, shares of Class B Common Stock of FS Development Corp. II converted into common stock of the Issuer. These shares are held by FSD Holdings II. Each of FCMVLLC, FCOMVLLC, Capital Fund V L.P., Opportunity Fund V L.P. and Dr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein. F2 · derivative.exercise_date: In connection with the closing of Pardes Biosciences, Inc.'s (formerly known as FS Development Corp. II) business combination, shares of Class B Common Stock of FS Development Corp. II converted into common stock of the Issuer. These shares are held by FSD Holdings II. Each of FCMVLLC, FCOMVLLC, Capital Fund V L.P., Opportunity Fund V L.P. and Dr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein. F2 · derivative.expiration_date: In connection with the closing of Pardes Biosciences, Inc.'s (formerly known as FS Development Corp. II) business combination, shares of Class B Common Stock of FS Development Corp. II converted into common stock of the Issuer. These shares are held by FSD Holdings II. Each of FCMVLLC, FCOMVLLC, Capital Fund V L.P., Opportunity Fund V L.P. and Dr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein. F2 · ownership.nature: In connection with the closing of Pardes Biosciences, Inc.'s (formerly known as FS Development Corp. II) business combination, shares of Class B Common Stock of FS Development Corp. II converted into common stock of the Issuer. These shares are held by FSD Holdings II. Each of FCMVLLC, FCOMVLLC, Capital Fund V L.P., Opportunity Fund V L.P. and Dr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein. Read SEC document
December 23, 2021 Filed Dec 28, 2021 21:30 UTC	PARDES BIOSCIENCES, INC. PRDS · Entity 110063	GrantCommon Stock	7,759,072	$0.00	$0.00	Disclosure SEC source: 0000899243-21-049928 · doc4.xml · nonDerivative · entry 3 Tananbaum James B. · CIK 0001581754 · Director · 10% owner Foresite Capital Fund V, L.P. · CIK 0001792204 · 10% owner Foresite Capital Management V, LLC · CIK 0001792206 · 10% owner Foresite Capital Opportunity Fund V, L.P. · CIK 0001792205 · 10% owner Foresite Capital Opportunity Management V, LLC · CIK 0001792207 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 7,759,072 F3 · kind: In connection with the closing of Pardes Biosciences, Inc.'s (formerly known as FS Development Corp. II) business combination, 4,237,940 shares and 1,273,577 shares of Series A Preferred Stock of the target company in the business combination (formerly known as Pardes Biosciences, Inc.), held, respectively, by Capital Fund V L.P. and Opportunity Fund V L.P., were converted into 5,966,140 and 1,792,932 shares of common stock, respectively, of the Issuer. Each of FCMVLLC, FCOMVLLC and Dr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein. F3 · ownership.nature: In connection with the closing of Pardes Biosciences, Inc.'s (formerly known as FS Development Corp. II) business combination, 4,237,940 shares and 1,273,577 shares of Series A Preferred Stock of the target company in the business combination (formerly known as Pardes Biosciences, Inc.), held, respectively, by Capital Fund V L.P. and Opportunity Fund V L.P., were converted into 5,966,140 and 1,792,932 shares of common stock, respectively, of the Issuer. Each of FCMVLLC, FCOMVLLC and Dr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein. Read SEC document
December 23, 2021 Filed Dec 28, 2021 21:30 UTC	PARDES BIOSCIENCES, INC. PRDS · Entity 110063	ConversionCommon Stock	4,873,750	$0.00	$0.00	Disclosure SEC source: 0000899243-21-049928 · doc4.xml · nonDerivative · entry 2 Tananbaum James B. · CIK 0001581754 · Director · 10% owner Foresite Capital Fund V, L.P. · CIK 0001792204 · 10% owner Foresite Capital Management V, LLC · CIK 0001792206 · 10% owner Foresite Capital Opportunity Fund V, L.P. · CIK 0001792205 · 10% owner Foresite Capital Opportunity Management V, LLC · CIK 0001792207 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 4,873,750 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: In connection with the closing of Pardes Biosciences, Inc.'s (formerly known as FS Development Corp. II) business combination, shares of Class B Common Stock of FS Development Corp. II converted into common stock of the Issuer. These shares are held by FSD Holdings II. Each of FCMVLLC, FCOMVLLC, Capital Fund V L.P., Opportunity Fund V L.P. and Dr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein. F2 · ownership.nature: In connection with the closing of Pardes Biosciences, Inc.'s (formerly known as FS Development Corp. II) business combination, shares of Class B Common Stock of FS Development Corp. II converted into common stock of the Issuer. These shares are held by FSD Holdings II. Each of FCMVLLC, FCOMVLLC, Capital Fund V L.P., Opportunity Fund V L.P. and Dr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein. Read SEC document
December 23, 2021 Filed Dec 28, 2021 21:30 UTC	PARDES BIOSCIENCES, INC. PRDS · Entity 110063	GrantCommon Stock	1,000,000	$10.00	$10,000,000.00	Disclosure SEC source: 0000899243-21-049928 · doc4.xml · nonDerivative · entry 1 Tananbaum James B. · CIK 0001581754 · Director · 10% owner Foresite Capital Fund V, L.P. · CIK 0001792204 · 10% owner Foresite Capital Management V, LLC · CIK 0001792206 · 10% owner Foresite Capital Opportunity Fund V, L.P. · CIK 0001792205 · 10% owner Foresite Capital Opportunity Management V, LLC · CIK 0001792207 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,000,000 F1 · kind: Each of Foresite Capital Fund V, L.P. ("Capital Fund V L.P.") and Foresite Capital Opportunity Fund V, L.P. ("Opportunity Fund V L.P."), the sole shareholders of FS Development Holdings II, LLC ("FSD Holdings II"), were issued 500,000 shares of common stock obtained in private placement of public securities on December 23, 2021. Foresite Capital Management V, LLC ("FCMVLLC") and Foresite Capital Opportunity Management V, LLC ("FCOMVLLC") are general partners, respectively, of Capital Fund V L.P. and Opportunity Fund V L.P. Each of FCMVLLC, FCOMVLLC and Dr. Tananbaum, in his capacity as managing member of each of FCMVLLC and FCOMVLLC, disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein. F1 · ownership.nature: Each of Foresite Capital Fund V, L.P. ("Capital Fund V L.P.") and Foresite Capital Opportunity Fund V, L.P. ("Opportunity Fund V L.P."), the sole shareholders of FS Development Holdings II, LLC ("FSD Holdings II"), were issued 500,000 shares of common stock obtained in private placement of public securities on December 23, 2021. Foresite Capital Management V, LLC ("FCMVLLC") and Foresite Capital Opportunity Management V, LLC ("FCOMVLLC") are general partners, respectively, of Capital Fund V L.P. and Opportunity Fund V L.P. Each of FCMVLLC, FCOMVLLC and Dr. Tananbaum, in his capacity as managing member of each of FCMVLLC and FCOMVLLC, disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein. Read SEC document
December 23, 2021 Filed Dec 30, 2021 21:30 UTC Amendment	PARDES BIOSCIENCES, INC. PRDS · Entity 110063	ConversionCommon Stock · Derivative	4,941,250	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0000899243-21-050105 · doc4a.xml · derivative · entry 2 Tananbaum James B. · CIK 0001581754 · Director · 10% owner Foresite Capital Fund V, L.P. · CIK 0001792204 · 10% owner Foresite Capital Management V, LLC · CIK 0001792206 · 10% owner Foresite Capital Opportunity Fund V, L.P. · CIK 0001792205 · 10% owner Foresite Capital Opportunity Management V, LLC · CIK 0001792207 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 4,941,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: In connection with the closing of Pardes Biosciences, Inc.'s (formerly known as FS Development Corp. II) business combination, shares of Class B Common Stock of FS Development Corp. II converted into common stock of the Issuer. These shares are held by FS Development Holdings II, LLC ("FSD Holdings II"). Each of Foresite Capital Management V, LLC ("FCMVLLC"), Foresite Capital Opportunity Management V, LLC ("FCOMVLLC"), Foresite Capital Fund V, L.P. ("Capital Fund V L.P."), Foresite Capital Opportunity Fund V, L.P. ("Opportunity Fund V L.P.") and Dr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein. F2 · derivative.exercise_date: In connection with the closing of Pardes Biosciences, Inc.'s (formerly known as FS Development Corp. II) business combination, shares of Class B Common Stock of FS Development Corp. II converted into common stock of the Issuer. These shares are held by FS Development Holdings II, LLC ("FSD Holdings II"). Each of Foresite Capital Management V, LLC ("FCMVLLC"), Foresite Capital Opportunity Management V, LLC ("FCOMVLLC"), Foresite Capital Fund V, L.P. ("Capital Fund V L.P."), Foresite Capital Opportunity Fund V, L.P. ("Opportunity Fund V L.P.") and Dr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein. F2 · derivative.expiration_date: In connection with the closing of Pardes Biosciences, Inc.'s (formerly known as FS Development Corp. II) business combination, shares of Class B Common Stock of FS Development Corp. II converted into common stock of the Issuer. These shares are held by FS Development Holdings II, LLC ("FSD Holdings II"). Each of Foresite Capital Management V, LLC ("FCMVLLC"), Foresite Capital Opportunity Management V, LLC ("FCOMVLLC"), Foresite Capital Fund V, L.P. ("Capital Fund V L.P."), Foresite Capital Opportunity Fund V, L.P. ("Opportunity Fund V L.P.") and Dr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein. F2 · ownership.nature: In connection with the closing of Pardes Biosciences, Inc.'s (formerly known as FS Development Corp. II) business combination, shares of Class B Common Stock of FS Development Corp. II converted into common stock of the Issuer. These shares are held by FS Development Holdings II, LLC ("FSD Holdings II"). Each of Foresite Capital Management V, LLC ("FCMVLLC"), Foresite Capital Opportunity Management V, LLC ("FCOMVLLC"), Foresite Capital Fund V, L.P. ("Capital Fund V L.P."), Foresite Capital Opportunity Fund V, L.P. ("Opportunity Fund V L.P.") and Dr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein. Read SEC document
December 23, 2021 Filed Dec 30, 2021 21:30 UTC Amendment	PARDES BIOSCIENCES, INC. PRDS · Entity 110063	ConversionCommon Stock	4,941,250	$0.00	$0.00	Disclosure SEC source: 0000899243-21-050105 · doc4a.xml · nonDerivative · entry 1 Tananbaum James B. · CIK 0001581754 · Director · 10% owner Foresite Capital Fund V, L.P. · CIK 0001792204 · 10% owner Foresite Capital Management V, LLC · CIK 0001792206 · 10% owner Foresite Capital Opportunity Fund V, L.P. · CIK 0001792205 · 10% owner Foresite Capital Opportunity Management V, LLC · CIK 0001792207 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 4,941,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: In connection with the closing of Pardes Biosciences, Inc.'s (formerly known as FS Development Corp. II) business combination, shares of Class B Common Stock of FS Development Corp. II converted into common stock of the Issuer. These shares are held by FS Development Holdings II, LLC ("FSD Holdings II"). Each of Foresite Capital Management V, LLC ("FCMVLLC"), Foresite Capital Opportunity Management V, LLC ("FCOMVLLC"), Foresite Capital Fund V, L.P. ("Capital Fund V L.P."), Foresite Capital Opportunity Fund V, L.P. ("Opportunity Fund V L.P.") and Dr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein. F2 · ownership.nature: In connection with the closing of Pardes Biosciences, Inc.'s (formerly known as FS Development Corp. II) business combination, shares of Class B Common Stock of FS Development Corp. II converted into common stock of the Issuer. These shares are held by FS Development Holdings II, LLC ("FSD Holdings II"). Each of Foresite Capital Management V, LLC ("FCMVLLC"), Foresite Capital Opportunity Management V, LLC ("FCOMVLLC"), Foresite Capital Fund V, L.P. ("Capital Fund V L.P."), Foresite Capital Opportunity Fund V, L.P. ("Opportunity Fund V L.P.") and Dr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein. Read SEC document
December 23, 2021 Filed Jun 10, 2022 20:17 UTC Amendment	PARDES BIOSCIENCES, INC. PRDS · Entity 110063	GrantStock Option (right to buy) · Derivative	75,000	$0.00 Strike: $9.80	$0.00	Disclosure SEC source: 0001209191-22-035869 · doc4a.xml · derivative · entry 1 Tananbaum James B. · CIK 0001581754 · Director · 10% owner Foresite Capital Fund V, L.P. · CIK 0001792204 · 10% owner Foresite Capital Management V, LLC · CIK 0001792206 · 10% owner Foresite Capital Opportunity Fund V, L.P. · CIK 0001792205 · 10% owner Foresite Capital Opportunity Management V, LLC · CIK 0001792207 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2031-12-22 F1 · derivative.exercise_date: This option shall vest in substantially equal monthly installments over three years, subject to a continued service relationship. The vested shares subject to such option shall be exercisable upon the effectiveness of the Issuer's registration statement on Form S-8, registering the shares of the Issuer's 2021 Stock Option and Incentive Plan with the U.S. Securities and Exchange Commission. Read SEC document
December 22, 2021 Filed Dec 23, 2021 21:52 UTC	PARDES BIOSCIENCES, INC. PRDS · Entity 110063	PurchaseCommon Stock	325,000	$10.00	$3,250,000.00	Disclosure SEC source: 0001213900-21-067341 · ownership.xml · nonDerivative · entry 1 Tananbaum James B. · CIK 0001581754 · Director · 10% owner Foresite Capital Fund V, L.P. · CIK 0001792204 · 10% owner Foresite Capital Management V, LLC · CIK 0001792206 · 10% owner Foresite Capital Opportunity Fund V, L.P. · CIK 0001792205 · 10% owner Foresite Capital Opportunity Management V, LLC · CIK 0001792207 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 325,000 F1 · kind: Each of Foresite Capital Fund V, L.P. ("Capital Fund V L.P.") and Foresite Capital Opportunity Fund V, L.P. ("Opportunity Fund V L.P.") purchased 162,500 shares of the Issuer's Class A Common Stock in a block trade at $10 per share on December 22, 2021. Foresite Capital Management V, LLC ("FCMVLLC") and Foresite Capital Opportunity Management V, LLC ("FCOMVLLC") are general partners, respectively, of Capital Fund V L.P. and Opportunity Fund V L.P. Each of FCMVLLC, FCOMVLLC and Dr. Tananbaum, in his capacity as managing member of each of FCMVLLC and FCOMVLLC, disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein. In connection with the closing of Pardes Biosciences, Inc.'s (formerly known as FS Development Corp. II) business combination, shares of the Issuer's Class A Common Stock were reclassified as common stock. F1 · ownership.nature: Each of Foresite Capital Fund V, L.P. ("Capital Fund V L.P.") and Foresite Capital Opportunity Fund V, L.P. ("Opportunity Fund V L.P.") purchased 162,500 shares of the Issuer's Class A Common Stock in a block trade at $10 per share on December 22, 2021. Foresite Capital Management V, LLC ("FCMVLLC") and Foresite Capital Opportunity Management V, LLC ("FCOMVLLC") are general partners, respectively, of Capital Fund V L.P. and Opportunity Fund V L.P. Each of FCMVLLC, FCOMVLLC and Dr. Tananbaum, in his capacity as managing member of each of FCMVLLC and FCOMVLLC, disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein. In connection with the closing of Pardes Biosciences, Inc.'s (formerly known as FS Development Corp. II) business combination, shares of the Issuer's Class A Common Stock were reclassified as common stock. Read SEC document
November 01, 2021 Filed Nov 3, 2021 20:17 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	OtherCommon Stock	8,276	$0.00	$0.00	Disclosure SEC source: 0001209191-21-062697 · doc4.xml · nonDerivative · entry 4 Foresite Capital Management III, LLC · CIK 0001645157 · 10% owner Foresite Capital Fund III, L.P. · CIK 0001645158 · 10% owner Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner Foresite Capital Management V, LLC · CIK 0001792206 · 10% owner Foresite Capital Fund V, L.P. · CIK 0001792204 · 10% owner Tananbaum James B. · CIK 0001581754 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 8,276 F5 · kind: Represents shares received by the James B. Tananbaum and Dana Shonfeld Tananbaum Family Trust pursuant to pro rata distributions by Fund III and FCM III, for no consideration, of shares of the Issuer's Common Stock to their respective partners or members, as applicable. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and/or 16a-9 of the Securities Exchange Act of 1934, as amended. F6 · ownership.nature: These shares are held of record by a family trust for which Mr. Tananbaum is a trustee. Each of the Reporting Persons disclaims the existence of a "group" and, other than Mr. Tananbaum, disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that any such person is the beneficial owner of such securities, except to the extent of such person's pecuniary interest therein, if any. Read SEC document
November 01, 2021 Filed Nov 3, 2021 20:17 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	OtherCommon Stock	1,954,904	$0.00	$0.00	Disclosure SEC source: 0001209191-21-062697 · doc4.xml · nonDerivative · entry 1 Foresite Capital Management III, LLC · CIK 0001645157 · 10% owner Foresite Capital Fund III, L.P. · CIK 0001645158 · 10% owner Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner Foresite Capital Management V, LLC · CIK 0001792206 · 10% owner Foresite Capital Fund V, L.P. · CIK 0001792204 · 10% owner Tananbaum James B. · CIK 0001581754 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 F1 · kind: On November 1, 2021, Foresite Capital Fund III, L.P. ("Fund III") distributed, for no consideration, 1,954,904 shares of the Issuer's Common Stock (the "Fund III Shares") to its limited partners and to Foresite Capital Management III, LLC ("FCM III"), the general partner of Fund III, representing each such partner's pro rata interest in such Fund III Shares. On the same date, FCM III distributed, for no consideration, the Fund III Shares it received in the distribution by Fund III to its members, representing each such member's pro rata interest in such Fund III Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and/or 16a-9 of the Securities Exchange Act of 1934, as amended. F2 · ownership.nature: The shares are owned directly by Fund III. FCM III is the general partner of Fund III, may be deemed to have sole voting and dispositive power over these shares. James B. Tananbaum ("Mr. Tananbaum") is the sole managing member of FCM III and may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM III and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM III or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document
February 19, 2021 Filed Feb 23, 2021 22:34 UTC	PARDES BIOSCIENCES, INC. FSII · Entity 110063	PurchaseClass A Common Stock	602,500	$10.00	$6,025,000.00	Disclosure SEC source: 0001213900-21-011174 · ownership.xml · nonDerivative · entry 1 FS Development Holdings II, LLC · CIK 0001822712 · 10% owner Foresite Capital Fund V, L.P. · CIK 0001792204 · 10% owner Foresite Capital Management V, LLC · CIK 0001792206 · 10% owner Tananbaum James B. · CIK 0001581754 · Director · President & CEO · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 602,500 F1 · kind: The reported shares of Class A common stock were purchased in a private placement by FS Development Holdings II, LLC (the "Sponsor") for $10.00 per share, as described under the heading "Description of Shares" in the Issuer's registration statement on Form S-1 (File No. 333-252435). F2 · ownership.direct: The Sponsor is the record holder of the shares reported herein. Foresite Capital Fund V, L.P. ("Fund V"), its general partner Foresite Capital Management V, LLC ("FCM V"), and Dr. James Tananbaum, the managing member of FCM V, have voting and investment discretion with respect to the common stock held of record by the Sponsor. Each of Fund V, FCM V, their respective members and Dr. Tananbaum disclaim beneficial ownership of these shares except to the extent of any pecuniary interest therein. Read SEC document
February 05, 2021 Filed Feb 9, 2021 20:04 UTC	Disc Medicine, Inc. GMTX · Entity 2273	ConversionCommon Stock · Derivative	2,928,750	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001213900-21-007713 · ownership.xml · derivative · entry 4 FS Development Holdings, LLC · CIK 0001820810 · 10% owner · Director by Deputization Foresite Capital Fund V, L.P. · CIK 0001792204 · 10% owner · Director by Deputization Foresite Capital Management V, LLC · CIK 0001792206 · 10% owner · Director by Deputization Foresite Capital Opportunity Fund V, L.P. · CIK 0001792205 · 10% owner · Director by Deputization Foresite Capital Opportunity Management V, LLC · CIK 0001792207 · 10% owner · Director by Deputization Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,928,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: In connection with the closing of Gemini Therapeutics, Inc.'s (formerly known as FS Development Corp.) business combination, shares of Class B Common Stock of FS Development Corp. converted into common stock of the Issuer . F3 · derivative.exercise_date: In connection with the closing of Gemini Therapeutics, Inc.'s (formerly known as FS Development Corp.) business combination, shares of Class B Common Stock of FS Development Corp. converted into common stock of the Issuer . F3 · derivative.expiration_date: In connection with the closing of Gemini Therapeutics, Inc.'s (formerly known as FS Development Corp.) business combination, shares of Class B Common Stock of FS Development Corp. converted into common stock of the Issuer . F2 · ownership.direct: These shares of the Issuer's common stock are held of record by FS Development Holdings, LLC ("FSD Holdings"). Foresite Capital Management V LLC ("FCMVLLC") and Foresite Capital Opportunity Management V, LLC ("FCOMVLLC") are general partners, respectively, of Foresite Capital Fund V, L.P. ("Capital Fund V L.P.") and Foresite Capital Opportunity Fund V, L.P. ("Opportunity Fund V .L.P."), the sole shareholders of FSD Holdings. Each of FCMVLLC, FCOMVLLC, Capital Fund V L.P and Opportunity Fund V L.P. disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein. Read SEC document
February 05, 2021 Filed Feb 9, 2021 20:04 UTC	Disc Medicine, Inc. GMTX · Entity 2273	ConversionCommon Stock	2,928,750	$0.00	$0.00	Disclosure SEC source: 0001213900-21-007713 · ownership.xml · nonDerivative · entry 2 FS Development Holdings, LLC · CIK 0001820810 · 10% owner · Director by Deputization Foresite Capital Fund V, L.P. · CIK 0001792204 · 10% owner · Director by Deputization Foresite Capital Management V, LLC · CIK 0001792206 · 10% owner · Director by Deputization Foresite Capital Opportunity Fund V, L.P. · CIK 0001792205 · 10% owner · Director by Deputization Foresite Capital Opportunity Management V, LLC · CIK 0001792207 · 10% owner · Director by Deputization Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,928,750 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: In connection with the closing of Gemini Therapeutics, Inc.'s (formerly known as FS Development Corp.) business combination, shares of Class B Common Stock of FS Development Corp. converted into common stock of the Issuer . F2 · ownership.direct: These shares of the Issuer's common stock are held of record by FS Development Holdings, LLC ("FSD Holdings"). Foresite Capital Management V LLC ("FCMVLLC") and Foresite Capital Opportunity Management V, LLC ("FCOMVLLC") are general partners, respectively, of Foresite Capital Fund V, L.P. ("Capital Fund V L.P.") and Foresite Capital Opportunity Fund V, L.P. ("Opportunity Fund V .L.P."), the sole shareholders of FSD Holdings. Each of FCMVLLC, FCOMVLLC, Capital Fund V L.P and Opportunity Fund V L.P. disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein. Read SEC document
February 05, 2021 Filed Feb 9, 2021 20:04 UTC	Disc Medicine, Inc. GMTX · Entity 2273	GrantCommon Stock	1,500,000	$10.00	$15,000,000.00	Disclosure SEC source: 0001213900-21-007713 · ownership.xml · nonDerivative · entry 1 FS Development Holdings, LLC · CIK 0001820810 · 10% owner · Director by Deputization Foresite Capital Fund V, L.P. · CIK 0001792204 · 10% owner · Director by Deputization Foresite Capital Management V, LLC · CIK 0001792206 · 10% owner · Director by Deputization Foresite Capital Opportunity Fund V, L.P. · CIK 0001792205 · 10% owner · Director by Deputization Foresite Capital Opportunity Management V, LLC · CIK 0001792207 · 10% owner · Director by Deputization Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,500,000 F1 · kind: Shares of common stock obtained in private placement of public securities ("PIPE") on February 5, 2021. F2 · ownership.direct: These shares of the Issuer's common stock are held of record by FS Development Holdings, LLC ("FSD Holdings"). Foresite Capital Management V LLC ("FCMVLLC") and Foresite Capital Opportunity Management V, LLC ("FCOMVLLC") are general partners, respectively, of Foresite Capital Fund V, L.P. ("Capital Fund V L.P.") and Foresite Capital Opportunity Fund V, L.P. ("Opportunity Fund V .L.P."), the sole shareholders of FSD Holdings. Each of FCMVLLC, FCOMVLLC, Capital Fund V L.P and Opportunity Fund V L.P. disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein. Read SEC document
December 07, 2020 Filed Dec 9, 2020 13:35 UTC	Kinnate Biopharma Inc. KNTE · Entity 92187	ConversionSeries C Preferred Stock · Derivative	48,376	$0.00	$0.00	Disclosure SEC source: 0001209191-20-062449 · doc4.xml · derivative · entry 12 Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner Foresite Capital Management V, LLC · CIK 0001792206 · 10% owner Foresite Capital Fund V, L.P. · CIK 0001792204 · 10% owner Foresite Capital Opportunity Management V, LLC · CIK 0001792207 · 10% owner Foresite Capital Opportunity Fund V, L.P. · CIK 0001792205 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 48,538 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Each share of the issuer's Series C Preferred Stock automatically converted into 1.00335008 share of Common Stock immediately prior to the completion of the issuer's public offering and had no expiration date. F6 · derivative.exercise_date: Each share of the issuer's Series C Preferred Stock automatically converted into 1.00335008 share of Common Stock immediately prior to the completion of the issuer's public offering and had no expiration date. F6 · derivative.expiration_date: Each share of the issuer's Series C Preferred Stock automatically converted into 1.00335008 share of Common Stock immediately prior to the completion of the issuer's public offering and had no expiration date. F3 · ownership.nature: The shares are owned directly by Foresite Capital Opportunity Fund V, L.P. ("Opportunity Fund V"). Foresite Capital Opportunity Management V, LLC ("FCOM V") is the general partner of Opportunity Fund V and may be deemed to have sole voting and dispositive power over these shares. James B. Tananbaum ("Dr. Tananbaum") is the sole managing member of FCOM V and may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCOM V and Dr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCOM V or Dr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document
December 07, 2020 Filed Dec 9, 2020 13:35 UTC	Kinnate Biopharma Inc. KNTE · Entity 92187	ConversionSeries C Preferred Stock · Derivative	145,128	$0.00	$0.00	Disclosure SEC source: 0001209191-20-062449 · doc4.xml · derivative · entry 11 Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner Foresite Capital Management V, LLC · CIK 0001792206 · 10% owner Foresite Capital Fund V, L.P. · CIK 0001792204 · 10% owner Foresite Capital Opportunity Management V, LLC · CIK 0001792207 · 10% owner Foresite Capital Opportunity Fund V, L.P. · CIK 0001792205 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 145,614 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Each share of the issuer's Series C Preferred Stock automatically converted into 1.00335008 share of Common Stock immediately prior to the completion of the issuer's public offering and had no expiration date. F6 · derivative.exercise_date: Each share of the issuer's Series C Preferred Stock automatically converted into 1.00335008 share of Common Stock immediately prior to the completion of the issuer's public offering and had no expiration date. F6 · derivative.expiration_date: Each share of the issuer's Series C Preferred Stock automatically converted into 1.00335008 share of Common Stock immediately prior to the completion of the issuer's public offering and had no expiration date. F3 · ownership.nature: The shares are owned directly by Foresite Capital Opportunity Fund V, L.P. ("Opportunity Fund V"). Foresite Capital Opportunity Management V, LLC ("FCOM V") is the general partner of Opportunity Fund V and may be deemed to have sole voting and dispositive power over these shares. James B. Tananbaum ("Dr. Tananbaum") is the sole managing member of FCOM V and may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCOM V and Dr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCOM V or Dr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document
December 07, 2020 Filed Dec 9, 2020 13:35 UTC	Kinnate Biopharma Inc. KNTE · Entity 92187	ConversionSeries C Preferred Stock · Derivative	157,222	$0.00	$0.00	Disclosure SEC source: 0001209191-20-062449 · doc4.xml · derivative · entry 10 Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner Foresite Capital Management V, LLC · CIK 0001792206 · 10% owner Foresite Capital Fund V, L.P. · CIK 0001792204 · 10% owner Foresite Capital Opportunity Management V, LLC · CIK 0001792207 · 10% owner Foresite Capital Opportunity Fund V, L.P. · CIK 0001792205 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 157,748 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Each share of the issuer's Series C Preferred Stock automatically converted into 1.00335008 share of Common Stock immediately prior to the completion of the issuer's public offering and had no expiration date. F6 · derivative.exercise_date: Each share of the issuer's Series C Preferred Stock automatically converted into 1.00335008 share of Common Stock immediately prior to the completion of the issuer's public offering and had no expiration date. F6 · derivative.expiration_date: Each share of the issuer's Series C Preferred Stock automatically converted into 1.00335008 share of Common Stock immediately prior to the completion of the issuer's public offering and had no expiration date. F3 · ownership.nature: The shares are owned directly by Foresite Capital Opportunity Fund V, L.P. ("Opportunity Fund V"). Foresite Capital Opportunity Management V, LLC ("FCOM V") is the general partner of Opportunity Fund V and may be deemed to have sole voting and dispositive power over these shares. James B. Tananbaum ("Dr. Tananbaum") is the sole managing member of FCOM V and may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCOM V and Dr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCOM V or Dr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document
December 07, 2020 Filed Dec 9, 2020 13:35 UTC	Kinnate Biopharma Inc. KNTE · Entity 92187	ConversionSeries B Preferred Stock · Derivative	18,641	$0.00	$0.00	Disclosure SEC source: 0001209191-20-062449 · doc4.xml · derivative · entry 9 Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner Foresite Capital Management V, LLC · CIK 0001792206 · 10% owner Foresite Capital Fund V, L.P. · CIK 0001792204 · 10% owner Foresite Capital Opportunity Management V, LLC · CIK 0001792207 · 10% owner Foresite Capital Opportunity Fund V, L.P. · CIK 0001792205 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 18,641 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each share of the issuer's Series B Preferred Stock automatically converted into one share of Common Stock immediately prior to the completion of the issuer's public offering and had no expiration date. F5 · derivative.exercise_date: Each share of the issuer's Series B Preferred Stock automatically converted into one share of Common Stock immediately prior to the completion of the issuer's public offering and had no expiration date. F5 · derivative.expiration_date: Each share of the issuer's Series B Preferred Stock automatically converted into one share of Common Stock immediately prior to the completion of the issuer's public offering and had no expiration date. F2 · ownership.nature: The shares are owned directly by Foresite Capital Fund V, L.P. ("Fund V"). Foresite Capital Management V, LLC ("FCM V") is the general partner of Fund V and may be deemed to have sole voting and dispositive power over these shares. James B. Tananbaum ("Dr. Tananbaum") is the sole managing member of FCM V and may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM V and Dr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM V or Dr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document
December 07, 2020 Filed Dec 9, 2020 13:35 UTC	Kinnate Biopharma Inc. KNTE · Entity 92187	ConversionSeries B Preferred Stock · Derivative	55,922	$0.00	$0.00	Disclosure SEC source: 0001209191-20-062449 · doc4.xml · derivative · entry 8 Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner Foresite Capital Management V, LLC · CIK 0001792206 · 10% owner Foresite Capital Fund V, L.P. · CIK 0001792204 · 10% owner Foresite Capital Opportunity Management V, LLC · CIK 0001792207 · 10% owner Foresite Capital Opportunity Fund V, L.P. · CIK 0001792205 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 55,922 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each share of the issuer's Series B Preferred Stock automatically converted into one share of Common Stock immediately prior to the completion of the issuer's public offering and had no expiration date. F5 · derivative.exercise_date: Each share of the issuer's Series B Preferred Stock automatically converted into one share of Common Stock immediately prior to the completion of the issuer's public offering and had no expiration date. F5 · derivative.expiration_date: Each share of the issuer's Series B Preferred Stock automatically converted into one share of Common Stock immediately prior to the completion of the issuer's public offering and had no expiration date. F2 · ownership.nature: The shares are owned directly by Foresite Capital Fund V, L.P. ("Fund V"). Foresite Capital Management V, LLC ("FCM V") is the general partner of Fund V and may be deemed to have sole voting and dispositive power over these shares. James B. Tananbaum ("Dr. Tananbaum") is the sole managing member of FCM V and may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM V and Dr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM V or Dr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document
December 07, 2020 Filed Dec 9, 2020 13:35 UTC	Kinnate Biopharma Inc. KNTE · Entity 92187	ConversionSeries B Preferred Stock · Derivative	2,666,002	$0.00	$0.00	Disclosure SEC source: 0001209191-20-062449 · doc4.xml · derivative · entry 7 Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner Foresite Capital Management V, LLC · CIK 0001792206 · 10% owner Foresite Capital Fund V, L.P. · CIK 0001792204 · 10% owner Foresite Capital Opportunity Management V, LLC · CIK 0001792207 · 10% owner Foresite Capital Opportunity Fund V, L.P. · CIK 0001792205 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 2,666,002 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each share of the issuer's Series B Preferred Stock automatically converted into one share of Common Stock immediately prior to the completion of the issuer's public offering and had no expiration date. F5 · derivative.exercise_date: Each share of the issuer's Series B Preferred Stock automatically converted into one share of Common Stock immediately prior to the completion of the issuer's public offering and had no expiration date. F5 · derivative.expiration_date: Each share of the issuer's Series B Preferred Stock automatically converted into one share of Common Stock immediately prior to the completion of the issuer's public offering and had no expiration date. F2 · ownership.nature: The shares are owned directly by Foresite Capital Fund V, L.P. ("Fund V"). Foresite Capital Management V, LLC ("FCM V") is the general partner of Fund V and may be deemed to have sole voting and dispositive power over these shares. James B. Tananbaum ("Dr. Tananbaum") is the sole managing member of FCM V and may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM V and Dr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM V or Dr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document
December 07, 2020 Filed Dec 9, 2020 13:35 UTC	Kinnate Biopharma Inc. KNTE · Entity 92187	ConversionSeries A Preferred Stock · Derivative	99,488	$0.00	$0.00	Disclosure SEC source: 0001209191-20-062449 · doc4.xml · derivative · entry 6 Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner Foresite Capital Management V, LLC · CIK 0001792206 · 10% owner Foresite Capital Fund V, L.P. · CIK 0001792204 · 10% owner Foresite Capital Opportunity Management V, LLC · CIK 0001792207 · 10% owner Foresite Capital Opportunity Fund V, L.P. · CIK 0001792205 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 99,488 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each share of the issuer's Series A Preferred Stock automatically converted into one share of Common Stock immediately prior to the completion of the issuer's public offering and had no expiration date. F4 · derivative.exercise_date: Each share of the issuer's Series A Preferred Stock automatically converted into one share of Common Stock immediately prior to the completion of the issuer's public offering and had no expiration date. F4 · derivative.expiration_date: Each share of the issuer's Series A Preferred Stock automatically converted into one share of Common Stock immediately prior to the completion of the issuer's public offering and had no expiration date. F1 · ownership.nature: The shares are owned directly by Foresite Capital Fund IV, L.P. ("Fund IV"). Foresite Capital Management IV, LLC ("FCM IV") is the general partner of Fund IV and may be deemed to have sole voting and dispositive power over these shares. James B. Tananbaum ("Dr. Tananbaum"), in his capacity as the sole managing member of FCM IV, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM IV and Dr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM IV or Dr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document
December 07, 2020 Filed Dec 9, 2020 13:35 UTC	Kinnate Biopharma Inc. KNTE · Entity 92187	ConversionSeries A Preferred Stock · Derivative	298,465	$0.00	$0.00	Disclosure SEC source: 0001209191-20-062449 · doc4.xml · derivative · entry 5 Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner Foresite Capital Management V, LLC · CIK 0001792206 · 10% owner Foresite Capital Fund V, L.P. · CIK 0001792204 · 10% owner Foresite Capital Opportunity Management V, LLC · CIK 0001792207 · 10% owner Foresite Capital Opportunity Fund V, L.P. · CIK 0001792205 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 298,465 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each share of the issuer's Series A Preferred Stock automatically converted into one share of Common Stock immediately prior to the completion of the issuer's public offering and had no expiration date. F4 · derivative.exercise_date: Each share of the issuer's Series A Preferred Stock automatically converted into one share of Common Stock immediately prior to the completion of the issuer's public offering and had no expiration date. F4 · derivative.expiration_date: Each share of the issuer's Series A Preferred Stock automatically converted into one share of Common Stock immediately prior to the completion of the issuer's public offering and had no expiration date. F1 · ownership.nature: The shares are owned directly by Foresite Capital Fund IV, L.P. ("Fund IV"). Foresite Capital Management IV, LLC ("FCM IV") is the general partner of Fund IV and may be deemed to have sole voting and dispositive power over these shares. James B. Tananbaum ("Dr. Tananbaum"), in his capacity as the sole managing member of FCM IV, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM IV and Dr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM IV or Dr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document
December 07, 2020 Filed Dec 9, 2020 13:35 UTC	Kinnate Biopharma Inc. KNTE · Entity 92187	ConversionSeries A Preferred Stock · Derivative	6,347,893	$0.00	$0.00	Disclosure SEC source: 0001209191-20-062449 · doc4.xml · derivative · entry 4 Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner Foresite Capital Management V, LLC · CIK 0001792206 · 10% owner Foresite Capital Fund V, L.P. · CIK 0001792204 · 10% owner Foresite Capital Opportunity Management V, LLC · CIK 0001792207 · 10% owner Foresite Capital Opportunity Fund V, L.P. · CIK 0001792205 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 6,347,893 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each share of the issuer's Series A Preferred Stock automatically converted into one share of Common Stock immediately prior to the completion of the issuer's public offering and had no expiration date. F4 · derivative.exercise_date: Each share of the issuer's Series A Preferred Stock automatically converted into one share of Common Stock immediately prior to the completion of the issuer's public offering and had no expiration date. F4 · derivative.expiration_date: Each share of the issuer's Series A Preferred Stock automatically converted into one share of Common Stock immediately prior to the completion of the issuer's public offering and had no expiration date. F1 · ownership.nature: The shares are owned directly by Foresite Capital Fund IV, L.P. ("Fund IV"). Foresite Capital Management IV, LLC ("FCM IV") is the general partner of Fund IV and may be deemed to have sole voting and dispositive power over these shares. James B. Tananbaum ("Dr. Tananbaum"), in his capacity as the sole managing member of FCM IV, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM IV and Dr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM IV or Dr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document
December 07, 2020 Filed Dec 9, 2020 13:35 UTC	Kinnate Biopharma Inc. KNTE · Entity 92187	ConversionCommon Stock	166,667	$0.00	$0.00	Disclosure SEC source: 0001209191-20-062449 · doc4.xml · nonDerivative · entry 3 Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner Foresite Capital Management V, LLC · CIK 0001792206 · 10% owner Foresite Capital Fund V, L.P. · CIK 0001792204 · 10% owner Foresite Capital Opportunity Management V, LLC · CIK 0001792207 · 10% owner Foresite Capital Opportunity Fund V, L.P. · CIK 0001792205 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 291,667 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · ownership.nature: The shares are owned directly by Foresite Capital Opportunity Fund V, L.P. ("Opportunity Fund V"). Foresite Capital Opportunity Management V, LLC ("FCOM V") is the general partner of Opportunity Fund V and may be deemed to have sole voting and dispositive power over these shares. James B. Tananbaum ("Dr. Tananbaum") is the sole managing member of FCOM V and may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCOM V and Dr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCOM V or Dr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document
December 07, 2020 Filed Dec 9, 2020 13:35 UTC	Kinnate Biopharma Inc. KNTE · Entity 92187	ConversionCommon Stock	500,001	$0.00	$0.00	Disclosure SEC source: 0001209191-20-062449 · doc4.xml · nonDerivative · entry 2 Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner Foresite Capital Management V, LLC · CIK 0001792206 · 10% owner Foresite Capital Fund V, L.P. · CIK 0001792204 · 10% owner Foresite Capital Opportunity Management V, LLC · CIK 0001792207 · 10% owner Foresite Capital Opportunity Fund V, L.P. · CIK 0001792205 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 875,001 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · ownership.nature: The shares are owned directly by Foresite Capital Fund V, L.P. ("Fund V"). Foresite Capital Management V, LLC ("FCM V") is the general partner of Fund V and may be deemed to have sole voting and dispositive power over these shares. James B. Tananbaum ("Dr. Tananbaum") is the sole managing member of FCM V and may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM V and Dr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM V or Dr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document
December 07, 2020 Filed Dec 9, 2020 13:35 UTC	Kinnate Biopharma Inc. KNTE · Entity 92187	ConversionCommon Stock	9,171,643	$0.00	$0.00	Disclosure SEC source: 0001209191-20-062449 · doc4.xml · nonDerivative · entry 1 Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner Foresite Capital Management V, LLC · CIK 0001792206 · 10% owner Foresite Capital Fund V, L.P. · CIK 0001792204 · 10% owner Foresite Capital Opportunity Management V, LLC · CIK 0001792207 · 10% owner Foresite Capital Opportunity Fund V, L.P. · CIK 0001792205 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 9,671,643 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.nature: The shares are owned directly by Foresite Capital Fund IV, L.P. ("Fund IV"). Foresite Capital Management IV, LLC ("FCM IV") is the general partner of Fund IV and may be deemed to have sole voting and dispositive power over these shares. James B. Tananbaum ("Dr. Tananbaum"), in his capacity as the sole managing member of FCM IV, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM IV and Dr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM IV or Dr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document
December 03, 2020 Filed Dec 4, 2020 20:57 UTC	Kinnate Biopharma Inc. KNTE · Entity 92187	GrantCommon Stock	125,000	$20.00	$2,500,000.00	Disclosure SEC source: 0001209191-20-061877 · doc4.xml · nonDerivative · entry 3 Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner Foresite Capital Management V, LLC · CIK 0001792206 · 10% owner Foresite Capital Fund V, L.P. · CIK 0001792204 · 10% owner Foresite Capital Opportunity Management V, LLC · CIK 0001792207 · 10% owner Foresite Capital Opportunity Fund V, L.P. · CIK 0001792205 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 125,000 F3 · ownership.nature: The shares are owned directly by Foresite Capital Opportunity Fund V, L.P. ("Opportunity Fund V"). Foresite Capital Opportunity Management V, LLC ("FCOM V") is the general partner of Opportunity Fund V and may be deemed to have sole voting and dispositive power over these shares. James B. Tananbaum ("Dr. Tananbaum") is the sole managing member of FCOM V and may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCOM V and Dr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCOM V or Dr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document
December 03, 2020 Filed Dec 4, 2020 20:57 UTC	Kinnate Biopharma Inc. KNTE · Entity 92187	GrantCommon Stock	375,000	$20.00	$7,500,000.00	Disclosure SEC source: 0001209191-20-061877 · doc4.xml · nonDerivative · entry 2 Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner Foresite Capital Management V, LLC · CIK 0001792206 · 10% owner Foresite Capital Fund V, L.P. · CIK 0001792204 · 10% owner Foresite Capital Opportunity Management V, LLC · CIK 0001792207 · 10% owner Foresite Capital Opportunity Fund V, L.P. · CIK 0001792205 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 375,000 F2 · ownership.nature: The shares are owned directly by Foresite Capital Fund V, L.P. ("Fund V"). Foresite Capital Management V, LLC ("FCM V") is the general partner of Fund V and may be deemed to have sole voting and dispositive power over these shares. James B. Tananbaum ("Dr. Tananbaum") is the sole managing member of FCM V and may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM V and Dr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM V or Dr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document
December 03, 2020 Filed Dec 4, 2020 20:57 UTC	Kinnate Biopharma Inc. KNTE · Entity 92187	GrantCommon Stock	500,000	$20.00	$10,000,000.00	Disclosure SEC source: 0001209191-20-061877 · doc4.xml · nonDerivative · entry 1 Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner Foresite Capital Management V, LLC · CIK 0001792206 · 10% owner Foresite Capital Fund V, L.P. · CIK 0001792204 · 10% owner Foresite Capital Opportunity Management V, LLC · CIK 0001792207 · 10% owner Foresite Capital Opportunity Fund V, L.P. · CIK 0001792205 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 500,000 F1 · ownership.nature: The shares are owned directly by Foresite Capital Fund IV, L.P. ("Fund IV"). Foresite Capital Management IV, LLC ("FCM IV") is the general partner of Fund IV and may be deemed to have sole voting and dispositive power over these shares. James B. Tananbaum ("Dr. Tananbaum"), in his capacity as the sole managing member of FCM IV, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM IV and Dr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM IV or Dr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document
August 14, 2020 Filed Oct 20, 2020 00:49 UTC	Disc Medicine, Inc. FSDC · Entity 2273	PurchaseClass A Common Stock	441,500	$10.00	$4,415,000.00	Disclosure SEC source: 0001213900-20-032139 · ownership.xml · nonDerivative · entry 1 FS Development Holdings, LLC · CIK 0001820810 · 10% owner Foresite Capital Fund V, L.P. · CIK 0001792204 · 10% owner Foresite Capital Management V, LLC · CIK 0001792206 · 10% owner Tananbaum James B. · CIK 0001581754 · Director · President & CEO · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 441,500 F1 · date: The transaction was inadvertently omitted from reporting due to an administrative oversight. F2 · kind: The reported shares of Class A common stock were purchased in a private placement by FS Development Holdings, LLC (the "Sponsor") for $10.00 per share, as described under the heading "Description of Securities" in the Issuer's registration statement on Form S-1 (File No. 333-240098). F3 · ownership.direct: The Sponsor is the record holder of the shares reported herein. Foresite Capital Fund V, L.P. ("Fund V"), its general partner Foresite Capital Management V, LLC ("FCM V"), and Dr. James Tananbaum, the managing member of FCM V, have voting and investment discretion with respect to the common stock held of record by the Sponsor. Each of Fund V, FCM V, their respective members and Dr. Tananbaum disclaim beneficial ownership of these shares except to the extent of any pecuniary interest therein. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.